"","Proposal Number","Publication"
"1","NF000002","LaJeunesse DR, Buckner SM, and Lake J, et al.  2004.  Three new Drosophila markers of intracellular membranes.  Biotechniques 36:2-6."
"2","NF000004","He HB, Guzman EA, Croxen A, et al.  2005.  Hepatocyte growth factor/c-Met signaling promotes phosphorylation of MITF in melanocytes.  J Invest Dermatol 124(4):A96.  American Society for Investigative Dermatology Meeting.
"
"3","NF000010","·Oh M, Scoles DR, Haipek C, et al. 2003. Genetic heterogeneity of stably transfected cell lines revealed by expression profiling with oligonucleotide microarrays. Jour. of Cell Biochem. In press."
"4","NF000014","Stephens K.  2003.  Genetics of neurofibromatosis 1-associated peripheral nerve sheath tumors.  Cancer Investigation 21:901-918."
"5","NF000015","Slattery WH.  2004.  Vestibular schwannoma growth rates in NF2 natural history consortium subjects.  Otol Neurotol 25(5):811-817."
"6","NF000015","Slattery WH.  2003.  Magnetic resonance imaging scanner reliability for measuring changes in vestibular schwannoma size.  Otol Neurotol 24(4):660-670."
"7","NF000015","Slattery WH.  2004.  Hearing changes after diagnosis in NF2.  Otol Neurotol 25(2):150-154."
"8","NF000017","Kim TJ, Cariappa A, Iacomini J. et al.  2002. Defective proliferative responses in B lymphocytes and thymocytes that lack neurofibromin.  Mol Immunol 38: 701-8. 
"
"9","NF000017","Tong J, Hannan F, Zhu Y, Bernards A, Zhong Y (2002): Neurofibromin regulates G protein-stimulated adenylyl cyclase activity. Nat Neurosci 5:95-6."
"10","NF000017","Bernards A (2003): GAPs galore!  A survey of putative Ras superfamily GTPase activating proteins in man and Drosphilia. Biochem Biophys Acta  1603:47-82."
"11","NF000017","Bernards A, Hariharan IK (2001): Of flies and men--studying human disease in Drosophila. Curr Opin Genet Dev 11:274-8."
"12","NF000020","Nunes F, Shen Y, Niida Y, et al.  2005.  Inactivation patterns of NF2 and DAL-1/4.1B (EPB41L3) in sporadic meningioma.  Cancer Genet Cytogenet 162:135-39."
"13","NF000020","Heinrich B, Hartmann, C, Stemmer-Rachamimov AO, et al.  2003. Multiple meningiomas: Investigating the molecular basis of sporadic and familial forms.  Int J Cancer 103:483-8."
"14","NF000020","Eckstein O, Stemmer-Rachamimov A, Nunes F, et al.  2005.  Multiple meningiomas in brain and lung due to acquired mutation of the NF2 gene.  Neurology 62:1904-5."
"15","NF000023","Aquirre A, Rizvi TA, Ratner N, et al.  2005.  Overexpression of EGF receptor confers migratory properties to non-migratory postnatal neural progenitors.  J Neurosci. 25(48):11092-106."
"16","NF000023","·Bennett MR, Rizvi TA, McKinnon R, and Ratner N. 2003. Aberrant growth and differentiation of oligodendrocyte progenitors in neurofibromatosis type 1 mutants. J. Neurosci. 23(18):7207-7217."
"17","NF000024","Golay X, Gillen J, van Zijl PC, Barker PB (2002): Scan time reduction in proton magnetic resonance spectroscopic imaging of the human brain. Magn Reson Med 47:384-7."
"18","NF000024","Horska A, Calhoun VD, Bradshaw DH, Barker PB (2002): Rapid method for correction of CSF partial volume in quantitative proton MR spectroscopic imaging. Magn Reson Med 48:555-8."
"19","NF000025","·Kang BS, D Cooper, F Jelen, et al., 2003.  PDZ-tandem of human syntenin:  Crystal structure and functional properties.  Structure 11:459-468.
"
"20","NF000025","Beom Sik Kang, David Cooper, Yancho Devedjiev, Urszula Derewenda, Zygmunt
Derewenda. The structure of the FERM domain of merlin, the neurofibromatosis
type 2 gene product. Acta Crystallographica D Biological Crystallography. 2002.
58 (Pt 3):381-91."
"21","NF000025","Beom Sik Kang, David Cooper, Filip Jelen, Yancho Devedjiev, Urszula Derewenda,
Zbigniew Dauter, Jacek Otlewski, Zygmunt S. Derewenda. PDZ-tandem of
human syntenin: crystal structure and functional properties. Structure. 2003.
11:459-468."
"22","NF000025","Beom Sik Kang, David Cooper, Yancho Devedjiev, Urszula Derewenda, Zygmunt S.
Derewenda. Molecular roots of egenerate specificity in syntenin¿s PDZ2 domain: reassessment of the PDZ recognition paradigm. Structure. 2003. 11:845-853."
"23","NF000025","Beom Sik Kang, Yancho Devedjiev, Ulla Derewenda, Zygmunt Derewenda. The PDZ2
21 Domain of Syntenin at Ultra-high Resolution: Bridging the Gap Between
Macromolecular and Small Molecule Crystallography. Journal of Molecular
Biology. 2004. 338:483-493."
"24","NF000025","·Kang BS, D Cooper, Y Devedjiev, et al., 2003.  Molecular roots of degenerate specificity in syntenin's PDZ2 domain:  Reassessment of the PDZ recognition paradigm.  Structure 11:845-853.
"
"25","NF000025","Kang BS, Cooper DR, Devedjiev Y, Derewenda U, Derewenda ZS (2002): The structure of the FERM domain of merlin, the neurofibromatosis type 2 gene product. Acta Crystallogr D Biol Crystallogr 58:381-91."
"26","NF000027","Dombi E, Solomon J, Gillespie AJ, et al.  2007. NF1 plexiform neurofibroma growth rate by volumetric MRI: relationship to age and body weight. Neurology 68(9):643-647."
"27","NF000029","Kim S, McAuliffe W, Zaritskaya L.  2004.  Selective induction of TR6/DcR3 release by bacterial antigens in human monocytes and a dendritic cell subset.  Infection and Immunity 72(1):89-93."
"28","NF000029","Chen J, Xu X-M, Underhill CB, et al.  2005.  Tachyplesin activates the classical complement pathway to kill tumor cells.  Cancer Res 65(11):4614-22."
"29","NF000029","Chen J, Zhang L, and Kim S. 2004.  Quantification and detection of DcR3, a decoy receptor in TNFR family.  J Immunol Methods 285(1):63-70."
"30","NF000029","Liu N, Xu XM, Chen J, et al.  2004.  A hyaluronan-binding peptide can inhibit tumor growth by interacting with Bcl-2.  International Journal of Cancer 109:49-57.
"
"31","NF000029","Xu XM, Chen Y, Chen J, Yang S, Gao F, Underhill CB, Creswell K, Zhang L (2003): A peptide with three hyaluronan binding motifs inhibits tumor growth and induces apoptosis. Cancer Research  63:5685-5690."
"32","NF000032","Williams JA, Su HS, Bernards A, Field J, Sehgal A (2001): A circadian output in Drosophila mediated by neurofibromatosis-1 and Ras/MAPK. Science 293:2251-2256."
"33","NF000032","Zhou GL, Zhou Y, King CC, et al.  2003.  Akt phosphorylation of serine 21 on Pak1 modulates Nck binding and cell migration.  
Mol Cell Biol 23(22):8058-8069.
"
"34","NF000032","Li Y, Gonzalez MI, Meinkoth JL, et al.  2003.  Lysophosphatidic acid promotes survival and differentiation of rat schwann cells. J Biol Chem 278(11):9585-9591."
"35","NF000035","Ingram DA, Hiatt K, King AJ, Fisher L, Shivakumar R, Derstine C, Wenning MJ, Diaz B, Travers JB, Hood A, Marshall M, Williams DA, Clapp DW (2001): Hyperactivation of p21(ras) and the hematopoietic-specific Rho GTPase, Rac2, cooperate to alter the proliferation of neurofibromin-deficient mast cells in vivo and in vitro. J Exp Med 194:57-69."
"36","NF000035","Haitt K, Ingram DA, Huddleston H, et al.  2003.  Loss of the Nf1 tumor suppressor gene decreases Fas antigen in myeloid cells.  Am. J. Pathology 164:1471-9."
"37","NF000035","Yang FC, Ingram DA, Chen S, et al.  2003.  Neurofibromin-deficient Schwann cells secrete a potent migratory stimulus for NF1 +/- mast cells.  J. Clin. Invest. 112:1581-1861."
"38","NF010016","Mcclatchey AI and Giovannini M.  2005.  Membrane organization and tumorigenesis-the NF2 tumor suppressor, Merlin.  Genes Dev 19(19):2265-2277."
"39","NF010022","Xu Y YQ (2003):  E-cadherin negatively regulates CD44-hyaluronan interaction and CD44-mediated tumor invasion and branching morphogenesis. J. Biol Chem  278:8661-8668."
"40","NF010042","Babovic-Vuksanovic D, Widemann BC, Dombi E, et al.  2007.  Phase I trial of pirfenidone in children with neurofibromatosis 1 and plexiform neurofibromas.  Pediatr Neurol 36:293-300."
"41","NF010051","Akhmametyeva EM, Mihaylova M, Luo H, et al.  2006.  Regulation of the neurofibromatosis 2 (NF2) promoter expression during early embryonic development.  Dev Dyn 23:2771-85."
"42","NF010051","Golovnina K, Blinov A, Akhmametyeva EM, et al.  2005.  Evolution and origin of merlin, the product of the neurofibromatosis type 2 tumor-suppressor gene.  J Evol Biol 5:69."
"43","NF010051","Neff BA, Welling DB, Akhmametyeva EM, et al.  2006.  The molecular biology of vestibular schwannomas: Dissecting the pathogenic process at the molecular level.  Otol Neurotol 27:197-208."
"44","NF010051","Neff, BA, Oberstein E, Lorenz M, et al.  2006.  Cyclin D1 and D3 Expression in Vestibular Schwannomas.  Laryngoscope 116:423-426."
"45","NF010051","Chang LS, Akhmametyeva EM, Mihaylova M,  et al.  2005.  Dissecting the molecular pathways in vestibular schwannoma tumorigenesis.  Recent Research Development in Genes & Genomes 1:1-33."
"46","NF010054","Aguirre A, Rizvi TA, Ratner N, et al.  2005.  Overexpression of the EGF receptor confers migratory properties to non-migratory postnatal neural progenitors.  J Neuroscience 25:11092-106."
"47","NF010054","Wu J, Crimmins J, Monk K, et al.  2006.  Perinatal EGFR blockade prevents peripheral nerve disruption in a model reminiscent of WHO Grade 1 neurofibroma.  Am J Pathol 168:1686-1696."
"48","NF010059","Ling BC, Wu J, Miller SJ, et al.  2005.  Role for the epidermal growth factor receptor in neurofibromatosis-related peripheral nerve tumorigenesis.  Cancer Cell 7:65-75."
"49","NF010059","Garza R, Hudson RW, Walter CA, et al. 2007. A mild mutator phenotype arises in malignancies associated with neurofibromatosis type 1.  Mutat Res 615:98-110."
"50","NF010059","Miller SJ, Li H, Rizvi TA, et al.  2003.  Brain lipid binding protein in axon-Schwann cell interactions and peripheral nerve tumorigenesis.  Mol Cell Biol 23:2213-2224."
"51","NF010093","·Denisenko-Nehrbass N, Goutebroze L, Galvez T, et al.  2003.  Association of Caspr/paranodin with tumor suppressor schwannomin/merlin and b1 integrin in the CNS.  J. Neurochem. 84:209-221.
"
"52","NF010093","Zhu Y, Guignard F, Zhao D, et al.  2005.  Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma.  Cancer Cell 8:119-130."
"53","NF010093","Kuns R, Kissil JL, Newsham IF, et al.  2005.  Protein 4.1B expression is induced in mammary epithelial cells during pregnancy and regulates their proliferation.  Oncogene 24:6502-6515."
"54","NF010093","Chao RC, Pyzel U, Firdlyand J, et al.  2005.  Therapy-induced malignant neoplasms in NF1 mutant mice.  Cancer Cell 8:337-348."
"55","NF010093","Stemmer-Rachamimov A, Louis D, Nielsen P, et al.  2004.  Comparative pathology of nerve sheath tumors in mouse models and humans.  Cancer Research 64:3718-3724."
"56","NF010093","Saotome I, Curto M, and McClatchey AI.  2004.  Ezrin is essential for epithelial organization and villus morphogenesis in the developing intestine.  Dev Cell 6:855-864."
"57","NF010093","Robanus-Maandag E, Giovannini M, et al.  2004.  Early Nf2 inactivation in neural crest derived cells hemizygous for p53 converts the tumor spectrum from osteogenic to peripheral nerve sheath tumors.  Oncogene 23:6541-6547."
"58","NF010093","·Le DT and Shannon KM.  2002.  Ras processing as a therapeutic target in hematologic malignancies.  Curr. Opin. Hematol. 9:308-315.
"
"59","NF010093","·Crone SA, Negro A, Trumpp A, Giovannini M, and Lee KF.  2003.  Colonic epithelial expression of ErbB2 is required for postnatal maintenance of the enteric nervous system.  Neuron 37(1):29-40.
"
"60","NF010093","Zhu Y, Harada T, Guignard F, et al.  2005.  Ablation of NF1 in CNS causes transient neural progenitor hyperplasia and is sufficient to induce optic gliomas.  Development 132:5577-5588."
"61","NF010093","·Fleury-Feith J, Lecomte C, Renier A, et al.  2003.  Hemizygosity of Nf2 is associated with increased susceptibility to asbestos-induced peritoneal tumours.  Oncogene 22:3799-3805.
"
"62","NF010093","·Gitler AD, Zhu Y, Lu MM, Parada LF, and Epstein JA.  2003.  Nf1 has an essential role in endothelial cells.  Nat. Genet. 33(1):75-79.
"
"63","NF010093","·Gutmann DH, Baker SJ, Giovannini M, Garbow J, and Weiss W.  2003.  Mouse models of human cancer consortium symposium on nervous system tumors.  Cancer Res. 63(11):3001-3004.
"
"64","NF010093","·Kissil JL, Wilker EW, Johnson KC, et al.  2003.  Merlin, the product of the Nf2 tumor suppressor gene, is an inhibitor of the p21-activated kinase, Pak1.  Mol Cell 12(4):841-849.
"
"65","NF010093","·Lallemand D, Curto M, Saotome I, Giovannini M, and McClatchey AI.  2003.  NF2 deficiency promotes tumorigenesis and metastasis by destabilizing adherens junctions.  Genes & Dev. 17(9):1090-1100.
"
"66","NF010093","·Manent J, Oguievetskaia X, Bayer J, Ratner N, and    Giovannini M.  2003.  Magnetic cell sorting for enriching Schwann cells from adult mouse peripheral nerves.            J. Neuroscience Meth. 123:167-173.
"
"67","NF010093","·McLaughlin ME and Jacks T.  2003.  Progesterone receptor expression in neurofibromas.  Cancer Research 63(4):752-755.
"
"68","NF010093","·McLaughlin ME and Jacks T.  2002.  Thinking beyond the tumor cell: Nf1 haploinsufficiency in the tumor environment.  Cancer Cell.
"
"69","NF010093","·McLaughlin ME and Jacks T.  2003.  Neurofibromatosis type 1.  Methods Mol Biol 222:223-237.
"
"70","NF010093","·McClatchey AI.  2003.  Merlin and ERM proteins: Unappreciated roles in cancer development?  Nat. Rev. Cancer 3:877-883.
"
"71","NF010093","·Utermark T, Aleko A, Lerche H, et al.  2003.  Quinidine impairs proliferation of neurofibromatosis type 2-deficient human malignant mesothelioma cells.  Cancer 97:1955-1962.
"
"72","NF010093","·Weiss BG and Shannon KM.  2003.  Mouse cancer models as a platform for performing preclinical therapeutic trials.  Curr. Opin. Genet. Dev. 13(1):84-89.
"
"73","NF010093","·Yajnik V, Paulding C, Sordella R, et al.  DOCK4, a GTPase activator, is disrupted during tumorigenesis.  Cell 112(5):673-684.
"
"74","NF010093","Le DT, Kong N, Zhu Y, et al.  2004.  Somatic inactivation of NF1 in hematopoietic cells results in a progressive myeloproliferative disorder.  Blood 103:4243-4250."
"75","NF010093","Weiss BG and Shannon KM.  2004.  Preclinical trials in mouse cancer models.  In Holland EC (Ed.), Mouse Models of Human Cancer.  Wiley-Liss, Hoboken, New Jersey."
"76","NF010093","Reilly KM, Tuskan RG, Christy E, et al.  2004.  Susceptibility to astrocytoma in mice mutant for Nf1 and Trp53 is linked to chromosome 11 and subject to epigenetic effects.  PNAS USA 101:3008-3013."
"77","NF010097","Wiederhold T, Lee MF, James M, et al.  2004.  Magicin, a novel cytoskeletal protein associates with the NF2 tumor suppressor merlin and Grb2.  Oncogene 23:8815-8825."
"78","NF010112","Li L Guris DL Okura M Imamoto A (2003): Translocation of CrkL to focal adhesions mediates integrin-induced migration downstream of Src family kinases. Mol Cell Biol. 23:2883-92."
"79","NF010126","Gatto CL, Walker BJ, and S Lambert.  2007.  Asymmetric ERM activation at the Schwann cell process tip is required in axon-associated motility.  J Cell Physio 210:122-132."
"80","NF010130","Yoon B, Herman H, Hu B, et al.  2005.  Rasgfr1 imprinting is regulated by a CTCF-dependent methylation-sensitive enhancer blocker.  Mol Cell Biol 25(24):11184-11190."
"81","NF010138","Donarum EA, Halperin RF., Stephan DA., et al. 2006. Cognitive dysfunction in NF1 knock-out mice may result from altered vescular trafficking of APP/DRD3 complex. BMC Neurosci. 8:7-22."
"82","NF010144","Li W, Cui Y, Kushner SA, et al.  2005.  The HMG-CoA reductase inhibitor Lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1.  Curr Biol 15:1961-1967."
"83","NF010149","Chong JA, Moran MM, Teichmann M, et al. 2005. TATA-binding protein (TBP)-like factor (TLF) is a functional regulator of transcription: reciprocal regulation of the neurofibromatosis type 1 and c-fos genes by TLF/TRF2 and TBP.
Mol Cell Biol. 25(7):2632-43. 
"
"84","NF020005","Dasgupta B, Dugan LL, and Gutmann DH.  2003.  The neurofibromatosis 1 gene product neurofibromin regulates pituitary adenylate cyclase activating polypeptide-mediated signaling in astrocytes.  J Neurosci 23:8949-8954."
"85","NF020005","Dasgupta B, Li W, Perry A, et al.  2005.  Glioma formation in neurofibromatosis 1 (NF1) reflects preferential activation of 
K-RAS in astrocytes.  Cancer Res 65:236-245.
"
"86","NF020005","Bajenaru ML, Hernandez MR, Perry A, et al.  2003.  Optic nerve glioma in mice requires astrocyte Nf1 gene inactivation and Nf1 brain heterozygosity.  Cancer Res 63:8573-8577."
"87","NF020005","Su W, Xing R, Guha A, et al.  2007.  Mice with GFAP-targeted loss of neurofibromin demonstrate increased axonal MET expression with aging.  Glia 55:723-733."
"88","NF020005","Daginakatte GC and Gutmann DH.  2007.  Neurofibromatosis-1 (Nf1) heterozygous brain microglia elaborate paracrine factors that promote Nf1-deficient astrocyte and glioma growth.  Hum Mol Genet 16:1098-1112."
"89","NF020005","Warrington NM, Woerner BM, Daginakatte GC, et al.  2007.  Spatiotemporal differences in CXCL12 expression and cyclic AMP underlie the unique pattern of optic glioma growth in neurofibromatosis type 1.  Cancer Res 67:8588-95."
"90","NF020005","Read TA, Hegedus B, Wechsler-Reya R, et al.  2006.  The nurobiology of neuro-oncology. 
Ann Neurol 60:3-11.
"
"91","NF020005","Gutmann DH, Hunter-Schaedle K, and Shannon KM.  2006.  Harnessing preclinical mouse models to inform human clinical cancer trials.  J Clin Invest 116:847-852."
"92","NF020005","Zhu Y, Harada T, Liu L, et al.  2005.  Inactivation of NF1 in CNS causes increased glial progenitor proliferation and optic glioma formation. Dev 132:5577-5588."
"93","NF020005","Dasgupta B, Yi Y, Hegedus B, et al.  2005.  Cerebrospinal fluid proteomic analysis reveals dysregulation of methionine aminopeptidase-2 expression in human and mouse neurofibromatosis 1-associated glioma. Cancer Res 65:9843-9850."
"94","NF020005","Bajenaru ML, Garbow JR, Perry A, et al.  2005.  Natural history of NF1-associated optic nerve glioma formation in mice.  Ann Neurol 57:119-127.
"
"95","NF020005","Rubin JB, Gutmann DH.  2005.  Neurofibromatosis 1:  A model for nervous system tumor formation?  Nature Rev Cancer 5:557-564."
"96","NF020005","Bajenaru ML, Garbow JR, Perry A, et al.  2005.  Natural history of NF1-associated optic nerve glioma formation in mice.  Ann Neurol 57:119-127."
"97","NF020005","Dasgupta B, Yi Y, Chen DY, et al.  2005.  Proteomic analysis reveals hyperactivation of the mTOR pathway in NF1-associated human and mouse brain tumors.  Cancer Res 65:2755-2760."
"98","NF020008","Terry J, Saito T, Subramanian S, et al.  2007.  TLE1 as a diagnostic immunohistochemical marker for synovial sarcoma emerging form gene expression profiling studies. Am J Surg Path 31:240-6."
"99","NF020013","Tang X, Jnag S-W, Brat D, et al.  2007.  Akt phosphorylation and phosphatodylinositol (3,4,5)P3 binding synergistically inhibit the tumor suppressive activity of merlin.  Nature Cell Biol 9(10):1199-207."
"100","NF020013","Rong R, Surace EI, Haipek CA, et al.  2004.  Serine 518 phosphorylation modulates merlin intramolecular association and binding to critical effectors important for NF2 growth suppression.  Oncogene 23:8447-8454."
"101","NF020013","Rong R, Tang X, Gutmann DH, et al.  2004.  Neurofibromatosis 2 (NF2) tumor suppressor merlin inhibits phosphatidylinositol 3-kinase through binding to PIKE-L.  Proc Natl Acad Sci USA 101:18200-18205."
"102","NF020015","Boyd C, Smith MJ, Kluwe L, et al.  2008.  Alterations in the SMARCB1 (INI1) tumor suppressor gene in familial schwannomatosis.  Clin Genet 74(4):358-366."
"103","NF020015","MacCollin M, Chiocca EA, Evans DG, et al.  2005.  Diagnostic criteria for schwannomatosis.  Neurology 64:1838-1845."
"104","NF020026","Yang FC, Chen S, Clegg T, et al., 2006.  Nf1+/-mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.  Hum Mol Genet 15(16):2421-2437.

"
"105","NF020029","Wang Y, Nicol GD, Clapp DW, et. al  2005.  Sensory neurons from Nf1 haploinsufficient mice exhibit increased excitability.  J Neurophysiol 94:3670-3676."
"106","NF020029","Hingtgen CM, Roy SL, Clapp DW, et al.  2006.  Stimulus-evoked release of neuropeptides is enhanced in sensory neurons from mice with a heterozygous mutation of the Nf1 gene.  Neuroscience 137:637-645."
"107","NF020033","
Cox S, Willliams S, Reczek E, et al.  2007.  A negative feedback signaling network underlies oncogene-induced senescence.  Cancer Cell 10(6):459-472.
"
"108","NF020033","Cox S, Willliams S, Reczek E, et al.  2006.  A negative feedback signaling network underlies oncogene-induced senescence.  Cancer Cell 10:459-72."
"109","NF020033","Johannessen C, Reczeck E, James MD, et al.  2005.  The mTOR pathway is critically regulated by the NF1 tumor suppressor. Proc Natl Acad Sci 102:8573-8578."
"110","NF020035","Bernards A and Settleman J.  2004.  GAP control: Regulating the regulators of small GTPases.  Trends Cell Biol 14:377-385."
"111","NF020035","2006.  Regulators and effectors of small GTPases: Ras family.  Balch WE, Der CJ, Hall A, Eds. pp 1-9."
"112","NF020035","Bernards A and Settleman J.  2005.  GAPs in growth factor signaling.  Growth Factors 23:143-9.

"
"113","NF020035","Bernards A.  2005.  Superfamily and interacting proteins database.  Regulators and Effectors of Small GTPases: Ras Family (Balch WE, Dr CJ, and Hall A Eds.)  Methods in Enzymology Volume 407."
"114","NF020035","Bernards A and Settleman J.  2007.  GEFs in growth factor signaling.  Growth Factors 25:355-361."
"115","NF020037","Stickney JT, Bacon WC, Rojas M, et al. 2004. Activation of the tumor suppressor merlin modulates its interaction with lipid rafts. Cancer Research 65: 2717-2724."
"116","NF020037","Meng JJ, Rojas M, Bacon WC, et al.  2004.  Analyzing protein-protein interactions of the cytoskeleton:  Special problems and issues, in Epidermal Cells:  Methods and Protocols, K. Turksen, ed. Humana Press, Inc. 289:341-357."
"117","NF020037","Kumar G, Co C, Ip W, et al.  2005.  Cell motility assays on tissue culture dishes via non-invasive confinement and release of cells, Langmuir 21: 9267-9272."
"118","NF020040","Stephens K.  2006.  Neurofibromatosis 1.  In Genomic Disorders: The Genomic Basis of Disease (Lupski JR and Stankiewicz PT Eds).  New Jersey: Humana Press, pp 207-219."
"119","NF020040","Siegel DH and Sybert VP.  2006.  Mosaicism in genetic skin disorders.  Pediatr Dermatol 23:87-92."
"120","NF020040","Lombillo VA and Sybert VP.  2005.  Mosaicism in cutaneous pigmentation.  Curr Opin Pediatr 17:494-500."
"121","NF020040","Stephens K.  2006.  Clinical molecular genetics of the neurofibromatoses.  In Neurocutaneous Syndromes in Children (Curatolo P and Riva D, Eds).  Mariani Foundation Pediatric Neurology Series, n.15.  Montrouge: John Libbey Eurotext."
"122","NF020040","De Raedt T, Stephens M, Heyns I, et al.  2006.  Conservation of hotspots for recombination in low-copy repeats associated with the NF1 microdeletion.  Nat Genet 38:1419-1423."
"123","NF020040","Stephens K, Weaver M, Leppig KA, et al.  Interstitial uniparental isodisomy at clustered breakpoint intervals is a frequent mechanism of NF1 inactivation in myeloid malignancies.  Blood 108:1684-9."
"124","NF020040","Stephens K.  Neurofibromatosis.  In Molecular Pathology in Clinical Practice (Leonard DGB, Ed).  New York: Springer ¿ Verlag (in press)."
"125","NF020042","Thaxton C, Lopera J, Bott M.  2006.  Phosphorylation of the NF2 tumor suppressor in schwann cells is mediated by Cdc42/Pak and requires paxillin binding.  Mol Cell Neurosci 34:231-242.

"
"126","NF020042","Thaxton C, Lopera J, Bott M, et al.  2008.  Neuregulin and laminin stimulate schwannomin phosphorylation in subconfluent schwann cells.  Oncogene 27(19):2705-2715."
"127","NF020042","Iacovelli J, Lopera J, Bott M, et al.  Forskolin reduces p27Kip levels to promote schwann cell proliferation in vitro.  Glia 55(16):1638-1647."
"128","NF020054","Clark MK, Scott SA, Wojtkowiak JW, et al.  2007.  Synthesis, biochemical, and cellular evaluation of farnesyl monophosphate prodrugs as farnesyltransferase inhibitors  J Med Chem 50:3274-82."
"129","NF020054","Donelson JL, Hodges B, MacDougall DD, et al.  2006.  Amide-substituted farnesyl cysteine analogs as inhibitors of human isoprenylcysteine carboxymethyltransferase. Biorg Med Chem Lett 16:4420-3."
"130","NF020054","Dilworth JT, Kraniak JM, Wojtkowiak JW, et al.  2006.  Molecular targets for emerging anti-tumor therapies for neurofibromatosis Type 1. Biochem Pharmacol 72:1485-92.

"
"131","NF020054","Mattingly RR, Kraniak JM, Dilworth JT, et al.  2006.  The MEK inhibitor PD184352/CI-1040 selectively induces apoptosis in malignant schwannoma cell lines. J Pharmacol Exp Ther 316:456-465."
"132","NF020054","Sane KM, Mynderse M, Lalonde DT, et al.  2010.  A novel geranylgeranyl transferase inhibitor in combination with lovastatin inhibits proliferation and induces autophagy in STS-26T MPNST cells.  J Pharmacol Exp Ther. 333(1):23-33.
"
"133","NF020054","Wojtkowiak JW., Gibbs RA., and Mattingly, RR. 2009. Working together: Farnesyl transferase inhibitors and statins block protein prenylation. Mol Cell Pharmacol.1:1-6."
"134","NF020064","Wu M, Wallace MR, and Muir D.  2006.  Nf1 haploinsufficiency augments angiogenesis.  Oncogene 25:2297-2303.
"
"135","NF020064","Wu M, Wallace MR, and Muir D.  2005.  Tumorigenic properties of neurofibromin-deficient Schwann cells in culture and as syngrafts in Nf1 knockout mice.  J Neurosci Res 82:357-367."
"136","NF020064","Perrin GQ, Fishbein L, Thomson SA, et al.  2007.  Plexiform neurofibromas developed in the mouse by xenograft of an NF1 tumor-derived Schwann cell line.  J Neurosci Res 85:1347-57."
"137","NF020064","Perrin GQ, Fishbein L, Thomson SA, et al.  2007.  An orthotopic xenograft model of intraneural NF1 MPNST suggests a potential association between steroid hormones and tumor cell proliferation.  Lab Invest 87:1092-1102."
"138","NF020064","Fishbein L, Zhang X, Fisher LB, et al.  2006.  In vitro studies of steroid hormones in Neurofibromatosis 1 tumors and Schwann cells.  Mol Carcinog 46:512-523."
"139","NF020087","Jindal HK, Yoshinaga K, Seo PS, et al.  2006.  Purification of the NF2 tumor suppressor protein from human erythrocytes.  Can J Neurol Sci 33:394-402."
"140","NF020087","Seo, P., Quinn BJ., Khan AA. et al. 2009. Identification of eythrocyte p55/MPP1 as a binding partner of NF2 tumor suppressor protein/merlin. Exp Biol Med 234:255-262."
"141","NF030006","Lavery W, Hall V, Yager JC, et al.  2007.  Phosphatidyl inositol 3-Kinase and Akt nonautonomously promote perineurial glial growth in Drosophila peripheral nerves.  J Neurosci 27:279-288."
"142","NF030006","
Howlett E, Lin CC, Lavery W, et al.  2008.  A PI3-kinase-mediated negative feedback regulates neuronal excitability.  PLoS Genet 4 e1000277.
"
"143","NF030008","de Bustos C, Diaz de Ståhl T, Piotrowski A, et al. 2006.  Analysis of genomic variation within a region containing complex segmental duplications on 22q11 using high resolution array-CGH. Genomics (in press)."
"144","NF030008","Diaz de Stahl T, Hansson CM, DeBustos C, et al.  2005.  High-resolution array-CGH profiling of germline and tumor- specific copy number alterations on chromosome 22 in patients affected with schwannomas. Hum Genet 118: 35-44."
"145","NF030008","Buckley P, Mantripragada K, Díaz de Ståhl T, et al.  2005.  Identification of genetic aberrationson chromosome 22 outside the NF2 locus in schwannomatosis and neurofibromatosis type. Hum Mut 26: 540-549."
"146","NF030008","Mantripragada KK, Thuresson AC, Piotrowski A, et al.  2005.  Identification of novel deletion breakpoints bordered by segmental duplications in the NF1 locus using high-resolution array-CGH. J Med Genet 43:28-38.

"
"147","NF030008","de Stahl TD, Hartmann C, de Bustos C, et al. 2005.  Chromosome 22 tiling-path array-CGH analysis identifies germ-line- and tumor-specific aberrations in patients with glioblastoma multiforme. Genes Chromosomes Cancer 44:161-169."
"148","NF030008","Ammerlaan A, de Bustos C, Ararou A, et al.  2005.  Localization of a putative low-penetrance ependymoma susceptibility locus to 22q11 using a chromosome 22 tiling-path genomic microarray. Genes Chromosomes Cancer 43:329-38.

"
"149","NF030008","Buckley PG, Jarbo C, Menzel U, et al.  2005.  Comprehensive DNA copy number profiling of meningioma using a chromosome 1 tiling-path microarray identifies novel candidate tumor suppressor loci.  Cancer Res 65:2653-61."
"150","NF030008","Benetkiewicz M, Piotrowski A, Diaz De Stahl T, et al.  2006.  Chromosome 22 array-CGH profiling of breast cancer delimited minimal common regions of genomic imbalances and revealed frequent intra-tumoral genetic heterogeneity.  Int J Oncol 29:935-945."
"151","NF030008","Benetkiewicz M, de Stahl TD, Gordor A, et al.  2006.  Identification of limited regions of genetic aberrations in patients affected with Wilms' tumor using a tiling-path chromosome 22 array.  Int J Cancer (published on line)."
"152","NF030008","Piotrowski A, Benetkiewicz M, Menzel U, et al.  2006.  Microarray-based survey of CpG islands identifies concurrent hyper- and hypomethylation patterns in tissues derived from patients with breast cancer.  Genes Chromosomes Cancer 45: 656-667."
"153","NF030008","Hansson CM, Buckley PG, Grigelioniene G, et al.  2007.  Comprehensive genetic and epigenetic analysis of sporadic meningioma for macro-mutations on 22q and micromutations within the NF2 locus.  BMC Genomics 8: 16."
"154","NF030009","Shapira S, Barkan B, Fridman E, et al.  2007.  The tumor suppressor neurofibromin confers sensitivity to apoptosis by Ras-dependent and Ras-independent pathways. Cell Death Differ 14:895-906."
"155","NF030009","Barkan B, Starinsky S, Friedman S, et al.  2006.  The Ras inhibitor farnesylthiosalicylic acid as a potential therapy for neurofibromatosis type 1.  Clin Cancer Res 12:5533-5542."
"156","NF030010","Miller SJ, Lan Z, Hardiman A, et al.  2010.  Inhibition of eyes absent homolog 4 expression induces malignant peripheral nerve sheath tumor necrosis.  Oncogene 29(3):368-79."
"157","NF030010","Miller SJ, Rangwala F, Williams J, et al.  2006.  Large-scale molecular comparison of human Schwann cells to malignant peripheral nerve sheath tumor cell lines and tissues.  Cancer Res 66(5):2584-2591."
"158","NF030010","Miller SJ, Jessen WJ, Mehta T, et al.  2009.  Integrative genomic analyses show altered schwann cell development in neurofibromatosis tumors and implicate SOX9 as an addicting oncogene.  EMBO Mol Med 1(4):236-248."
"159","NF030015","Hyman SL., Gill DS., Shores EA. et al. 2007. T2 hyperintensities in children with neurofibromatosis type 1 and their relationship to cognitive functioning. J Neurol Neurosurg Psychiatry. 78:1088-1091"
"160","NF030015","Lorenzo J, Barton B, Arnold SS, and North KN. (2013) Cognitive features that distinguish preschool-age children with neurofibromatosis type 1 from their peers: a matched case-control study. J Pediatr 163(5):1479-83."
"161","NF030015","Lorenzo J, Barton B, Arnold SS, and North KN. (2015) Developmental trajectories of young children with neurofibromatosis type 1: a longitudinal study from 21 to 40 months of age. J Pediatr 166(4):1006-12"
"162","NF030015","Payne JM, Hyman SL, Shores EA, et al. 2011. Assessment of executive function and attention in children with neurofibromatosis type 1: Relationships between cognitive measures and real-world behavior. Child Neuropsychology 17(4):313-329."
"163","NF030015","Lorenzo J, Barton B, Acosta MT, and North K.  2011.  Mental, motor, and language development of toddlers with neurofibromatosis type 1. J Pediatr 158(4):660-5."
"164","NF030020","Surace EI, Strickland A, Gutmann DH, et al.  2006. Tslc1 (nectin-like molecule-2) is essential for spermatozoa motility and male fertility.  J Androl 27:816-25."
"165","NF030020","Maurel P, Einheber S, Galinska J, et al.  2007.  Nectin-like proteins mediate axon-Schwann cell interactions along the internode and are essential for myelination.  J Cell Biol 178:861-74."
"166","NF030020","Chadee DN, Hung G, Andalibi A, et al.  2006.  MLK3 regulates B-Raf through a mechanism that involves maintenance of the B-Raf/Raf-1 complex and inhibition by the NF2 tumor suppressor protein.  Proc Natl Acad Sci USA 103:4463-4468."
"167","NF030020","Houshmandi SS, Surace EI, Zhang H, et al.  2006.  Tumor suppressor in lung cancer-1 (TSLC1) functions as a glioma tumor suppressor.  Neurology 67:1863-1866."
"168","NF030020","Lau Y-KI, Murray L, Houshmandi SS, et al.  2008.  Merlin is a potent inhibitor of glioma growth.  Cancer Res 68:5733-5742."
"169","NF030020","Houshmandi SS and Gutmann DH.  2007.  All in the family: Using inherited cancer syndromes to understand de-regulated cell signaling in brain tumors.  J Cell Biochem 102:811-819."
"170","NF030020","Gerber MA, Bahr SM, and Gutmann DH.  2006.  Protein 4.1B/DAL-1 functions as a growth suppressor in meningioma cells by activating Rac1-dependent JNK signaling.  Cancer Res 66:5295-5303."
"171","NF030020","Yamada D, Kikuchi S, Williams YN, et al.  2005.  Promoter hypermethylation of the DAL-1/4.1B gene is correlated with poor prognosis in renal clear cell carcinoma.  Int J Cancer 118:916-923."
"172","NF030020","Singh V, Miranda TB, Jiang W, et al.  2004.  The DAL-1/4.1B tumor suppressor interacts with protein arginine N-methyltransferase 3 (PRMT3) and inhibits its ability to methylate substrates in vitro and in vivo.  Oncogene 23:7761-7771."
"173","NF030020","Robb VA, Gerber MA, Hart-Mahon EK, et al.  2005.  Membrane localization of the U2 domain of Protein 4.1B is necessary and sufficient for meningioma growth suppression.  Oncogene 24:1946-1957."
"174","NF030020","Houshmandi SS, Emnett RJ, Giovannini M, et al.  2009.  The neurofibromatosis-2 protein, merlin, regulates glial cell growth in an ErbB2- and Src-dependent manner.  Mol Cell Biol 29:1472-1486."
"175","NF030020","Surace EI, Lusis E, Murakami Y, et al.  2004.  Loss of tumor suppressor in lung cancer-1 (TSLC1) expression in meningioma correlates with increased malignancy grade and reduced patient survival.  J Neuropathol Exp Neurol 63:1015-1027."
"176","NF030039","Prabhakar S, Messerli SM, Stemmer-Rachamimov AO, et al.  2007.  Breakefield XO treatment of implantable NF2 schwannoma tumor models with oncolytic herpes simplex virus G47delta.  Cancer Gene Ther 14: 460-7."
"177","NF030039","Liu TC, Zhang T, Fukuhara H, et al.  2006.  Dominant-negative FGF receptor expression enhances antitumoral ptency of oncolytic HSV in neural tumors.  Clin Cancer Res 15;12(22):6791-6799."
"178","NF030039","Prabhakar S, Messerli S, Rabkin S, et al.  2006.  Treatment of experimental schwannomas  with HSV recombinant and amplicon vectors.  Mol Ther 13:S59."
"179","NF030039","Messerli SM, Prabhakar S, Tang Y, et al.  2006.  Treatment of schwannomas with an oncolytic recombinant herpes simplex virus in murine models of neurofibromatosis type 2. Human Gene Ther 17:20-30."
"180","NF030056","Walker JA, and Bernards A.  2007.  Drosophila neurofibromatosis-1: ROS, not Ras?  Nature Genet 39:443-445.

"
"181","NF030056","Walker JA, Tchoudakova AV, McKenney PT, et al.  2006.  Reduced growth of Drosophila neurofibromatosis 1 mutants reflects a non-cell-autonomous requirement for GTPase activating protein activity in larval neurons.  Gene Dev 20:3311-3323."
"182","NF030058","Ho IS*, Hannan F*, Guo H-F, et al.  2007.  Distinct functional domains of Neurofibromatosis Type 1 immediate versus long-term memory formation, J Neurosci, 27:6852-6857 (* equal first authorship)."
"183","NF030063","Park CS., Zhong L., and  Tang S-J.  2009. Aberrant Expression of Synaptic Plasticity-Related Genes in the NF1+/- Mouse Hippocampus. J Neurosci Res 7:3107-3119."
"184","NF030070","Neff BA, Oberstein E, Lorenz M, et al.  2006. Cyclin D1 and D3 expression in vestibular schwannomas.  Laryngoscope 116:423-426."
"185","NF030070","Neff BA, Welling DB, Akhmametyeva EM, et al.  2006.  The molecular biology of vestibular schwannomas:  Dissecting the pathogenic process at the molecular level.  Otol Neurotol 27:197-208.

"
"186","NF030070","Chang L-S, Jacob A, Lorenz M, et al.  2006.  Magnetic resonance imaging noninvasively quantifies schwannoma xenografts in SCID mice.  Laryngoscope 116:2018-2026."
"187","NF030070","Golovnina K, Blinov A, Akhmametyeva EM, et al.  2005.  Evolution and origin of merlin, the product of the neurofibromatosis type 2 tumor-suppressor gene.  J Evol Biol 5:69."
"188","NF030070","Jacob A, Lee TX, Neff BA, et al.  2008.  Activation of the AKT pathway in human vestibular schwannomas.  Otol Neurotol 29:58-68."
"189","NF030070","Dorogova NV, Akhmametyeva EM, Kopyl SA, et al.  2008.  The role of merlin in spermatogenesis.  BMC Cell Biology 9:1-15."
"190","NF030070","Akhmametyeva EM, Mihaylova MM, Luo H, et al.  2006. Regulation of the NF2 gene promoter expression during embryonic development.  Dev Dyn 235:2771-2785."
"191","NF030078","Harashima T and Heitman J.  2005.  G-alpha&#61472;subunit Gpa2 recruits kelch repeat subunits that inhibit receptor-G protein coupling during cAMP induced dimorphic transitions in Saccharomyces cerevisiae. Mol Biol Cell 16:4557-4571."
"192","NF030078","Bahn YS, Xue C, Idnurm A, et al.  2007.  Sensing the environment: lessons from fungi.  Nat Rev Microbiol 5(1):57-69."
"193","NF030078","Harashima T, Anderson S, Yates JR III, et al.  2006.  The kelch proteins Gpb1 and Gpb2 inhibit Ras activity via association with the yeast RasGAP neurofibromin homologs Ira1 and Ira2.  Molecular Cell 22:819¿830."
"194","NF030078","Rutherford J, Chua G, Hughes T, et al.  2008.  A Mep2-dependent transcriptional profile links permease function to gene expression during pseudohyphal growth in Saccharomyces cerevisiae.  Mol Biol Cell 19:3028-39.
"
"195","NF030086","Hu D, Cao P, Thiels E, et al.  2007.  Hippocampal long-term potentiation, memory and longevity in mice that overexpress mitochondrial superoxide dismutase.  Neurobiol Learn Mem 87:327-384."
"196","NF030086","Lauver A, Yuan LL, Jeromin A, et al.  2006.  Manipulating Kv4.2 identifies a specific component of hippocampal pyramidal neuron A-current that depends upon Kv4.2 expression.  J Neurochem 99:1207-1223."
"197","NF030086","Swank MW, Kumar V, Zhao J, et al.  2006.  Novel method of loading samples onto mini-gels for SDS- PAGE:  increased sensitivity and western blots using sub-microgram quantities of protein.  J Neurosci Methods 158:224-233."
"198","NF030086","Kumar V, Zhang MX, Swank MW, et al.  2005.  Regulation of dendritic morphogenesis by Ras-PI3K-Akt-mTOR and Ras-MAPK signaling pathways.  J Neurosci 25:11288-11299."
"199","NF030086","Ryan XP, Alldritt JL, Allen P, et al. 2005.  The rho-specificGEF, Lfc, interacts with neurabin and spinophilin to regulate dendritic spine morphology.  Neuron 47:85-100."
"200","NF030086","Long C, Cook L, Hamilton S, et al.  2007.  FKBP12/12.6 deletion increases endothelial nitric oxide synthase threonine 495 phosphorylation and blood pressure in mice.  Hypertension 49:569-76."
"201","NF030086","Tejada-Simon MV, Serrano F, Villasana LE, et al.  Synaptic localization of a functional NADPH oxidase in the mouse hippocampus.  MCN 29:97-106."
"202","NF030086","Bryan B, Cai Y, Wrighton K, et al. 2005.  Smurf1 promotes dendritic outgrowth and dendritic spine morphorgensis via ubiquitination of RhoA.  FEBS Letters 579:1015-1019."
"203","NF043008","Laulajainen M, Muranen T, Carpan O, et al.  2008.  Protein kinase A mediated phosphorylation of the NF2 tumor suppressor protein merlin at serine 10 affects actin cytoskeleton.  Oncogene 27:3233-3243."
"204","NF043008","Mauranen T, Groonholm M, Lampin A, et al.  2007.  The tumor suppressor merlin interacts with microtubules and modulates Schwann cell microtubule cytoskeleton.  Hum Mol Genet 16:1742-51."
"205","NF043008","Muranen T., M. Grönholm, G.H. Renkema, O. Carpén. Cell cycle dependent nucleo-cytoplasmic shuttling of the neurofibromatosis 2 tumour suppressor merlin. Oncogene. 24:1150-1158, 2005."
"206","NF043008","Heiska L and Carpén O.  2005.  Src phosphorylates ezrin at tyrosine 477 and induces a phosphospecific interaction between ezrin and a kelch-repeat protein family member.  J Biol Chem 280:10244-10252."
"207","NF043008","Grönholm M, Muranen T, Toby G, et al.  2006.  A functional association between merlin and HEI10, a cell cycle regulator.  Oncogene 25:4389-4398."
"208","NF043019","Munchhof AM, Li F, White HA, et al.  2006.  Neurofibroma-associated growth factors activate a distinct signaling network to alter the function of neurofibromin-deficient endothelial cells. 
Hum Mol Genet 15(11):1858-1869.

"
"209","NF043019","Wu X, Estwik SA, Chen S, et al.  2006.  Neurofibromin plays a critical role in modulating osteoblast differentiation of mesenchymal stem/progenitor cells.  Hum Mol Genet 15(19):2837-2845."
"210","NF043019","Yang FC, Chen S, Robling AG, et al.  2006.  Hyperativation of p21ras and P13K cooperate to alter murine and human neurofibromatosis type 1-haploinsufficient osteoclast functions.  J Clin Invest 116(11):2880-2891."
"211","NF043032","A.M. Munchhof, F. Li, H.A. White, et al. 2006. Neurofibroma-associated growth factors activate a distinct signaling network to alter the function of neurofibromin-deficient endothelial cells. Human Molecular Genetics 15:1858-1869."
"212","NF043032","Si Y, Ciccone S, Yang F-C, et al.  2006.  Continuous in vivo infusion of interferon-gamma (IFN-[gamma]) enhances engraftment of syngeneic wild-type cells in Fanca-/- and Fancg-/- mice. Blood 108:4283-7."
"213","NF043032","Haneline LS, White H, Yang F-C, et al.  2006.  Genetic reduction of class IA PI-3 kinase activity alters fetal hematopoiesis and competitive repopulating ability of hematopoietic stem cells in vivo.  Blood 107:1375-1382."
"214","NF043032","Li F, Munchhof AM, White HA, et al.  2006.  Neurofibromin is a novel regulator of RASinduced signals in primary vascular smooth muscle cells.  Hum Mol Genet 15:1921-1930."
"215","NF043032","Nebesio TD, Ming W, Chen S, et al.  2006.  Neurofibromin-deficient Schwann cells have increased lysophosphatidic acid dependent survival and migration-implications for increased neurofibroma formation during pregnancy.  Glia 55:527-536."
"216","NF043032","Yang F-C, Chen S, Clegg T, et al.  2006.  Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-b signaling. Human Molecular Genetics 16:1-17."
"217","NF043032","Sharma R, Wu X, Rhodes SD, et al.  2013.  Hyperactive Ras/MAPK signaling is critical for tibial nonunion fracture in neurofibromin-deficient mice.  Hum Mol Genet 22(23):4818-4828."
"218","NF043032","Yan J et al. 2008. Rac1 mediates the osteoclast gains-in-function induced by haploinsufficiency of Nf1. Hum Mol Genet 17(7):936-948."
"219","NF043032","Yang FC, Chen S, Robling AG, et al. 2006. Hyperativation of p21ras and P13K cooperate to alter murine and human neurofibromatosis type 1-haploinsufficient osteoclast functions. J Clin Invest 116(11):2880-2891."
"220","NF043032","Wu X, Chen S, He Y, et al.  2011.  The haploinsufficient hematopoietic microenvironment is sufficient to normalize the pathological fracture repair in genetically engineered murine models of neurofibromatosis type 1.  PLoS One 6(9):e24917."
"221","NF043037","Deacon SW, Beeser A, Fukui JA, et al.  2008.  An isoform-selective, small-molecule inhibitor targets the autoregulatory mechanism of p21-activated kinase.  Chem Biol 15:322-331."
"222","NF043037","Eswaran J, Lee WH, Debreczeni JE, et al.  2007.  Crystal structures of the p21-activated kinases PAK4, PAK5, PAK6 reveal catalytic domain plasticity of active Group II PAKs.  Structure 15:201-213."
"223","NF043037","Rennefahrt UEE, Deacon S, Parker SA, et al.  2007.  Specificity profiling of Pak kinases allows identification of novel phosphorylation sites.  J Biol Chem 282 (21):15667-15678."
"224","NF043037","Deacon SW and Peterson JR. 2008. Chemical inhibition through conformational stabilization of Rho GTPase effectors.  In: Protein-protein Interaction Sites and Scaffoldling Proteins as Potential Drug Targets.  Springer."
"225","NF043037","Flaiz C, Chernoff J, Ammoun S, et al.  2009.  PAK kinase regulates Rac GTPase and is a potential target in human schwannomas.  Exp Neurol 218(1):137-44."
"226","NF043037","Viaud J. and Peterson JR. 2009. An allosteric kinase inhibitor binds the p21-activated kinase autoregulatory domain covalently. Mol Cancer Ther. 8:2559-2565."
"227","NF043040","Curto M, Cole BK, Lallemand D, et al.  2007.  Contact dependent inhibition of EGFR signaling by Nf2/Merlin.  J Cell Biol 177(5):893-903."
"228","NF043040","McClatchey AI and RG Fehon.  2009.  Merlin and ERM proteins -- regulators of receptor distribution and signaling at the cell cortex.  Trends Cell Biol 19(5):198-206."
"229","NF043040","Curto M and McClatchey AI.  2008.  Nf2/Merlin: A coordinator of receptor signaling and intercellular contact.  Br J Cancer 98(2):256-262"
"230","NF043040","Cole BK, Curto M, Chan AW, et al.  2008.  Localization to the cortical cytoskeleton is necessary for Nf2/Merlin-dependent epidermal growth factor receptor silencing.  Mol Cell Biol 28(4):1274."
"231","NF043043","Lepont P, Stickney JT, Foster LA, et al.  2007.  Point mutation in the NF2 gene of HEI-193 schwannoma cells results in expression of a non-growth suppressive merlin isoform.  Mutat Res 637:142-151."
"232","NF043050","Cui Y, Costa RM, Murphy GG, et al.  2008.  Neurofibromin regulation of ERK signaling modulates GABA release and learning.  Cell 135(3):549-560."
"233","NF043050","Bonilha VL, Rayborn ME, Saotome I, et al.  2006.  Microvilli defects in retinas of ezrin knockout mice.  Exp Eye Res 82:720-729."
"234","NF043050","Parada LF, Kwon CH, and Zhu Y.  2005.  Modeling neurofibromatosis type 1 tumors in the mouse for therapeutic intervention.  Cold Spring Harbor Symposia on Quantitative Biology.  Molecular Approaches to Controlling Cancer 70:173-176."
"235","NF043050","Yang F, Chen S, Clegg T, et al.  2006.  Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.  Hum Mol Genet 15:2421-2437."
"236","NF043050","Elefteriou F, Benson MD, Sowa H, et al.  2006.  ATF4 mediation of NF1 pathology in bone reveals a nutritional basis for congenital skeletal dysplasia.  Cell Metab 4:441-451."
"237","NF043050","Kim A, Morgan K, Hasz DE, et al.  2007.  Beta  common receptor inactivation attenuates myeloproliferative disease in Nf1 mutant mice.  Blood 109:1687-91."
"238","NF043050","Curto M, Cole BK, Lallemand D, et al.  2007.  Contact-dependent inhibition of EGFR signaling by Nf2/Merlin.  J Cell Biol 177:893-903."
"239","NF043050","Cole B, Curto M, McClatchey AI.  2008.  Localization to the cortical cytoskeleton is necessary for Nf2/Merlin-dependent EGFR silencing.  Mol Cell Biol 28:1274-84."
"240","NF043050","Schubbert S, Shannon K, Bollag G.  2007.  Hyperactive Ras signaling in developmental disorders and cancer.  Nat Reviews Cancer 7:295-308."
"241","NF043050","Diaz-Flores E and Shannon K.  2007.  Targeting oncogenic Ras.  Genes Develop 21:1989-1992."
"242","NF043050","Kolanczyk M, Kossler N, Kuhnisch J, et al.  2007.  Multiple roles for neurofibromin in skeletal development and growth.  Human Mol Genet 16:874-886."
"243","NF043050","Romero MI, Lin L, Lush ME, et al.  2007.  Deletion of NF1 in neurons induces increased axon collateral branching after dorsal root injury.  J Neuroscience 27:2124-2134.

"
"244","NF043050","Le L and Parada LF.  2007.  Tumor microenvironment and neurofibromatosis type I:Connecting the GAPs.  Oncogene 12:26(32):4609-4616."
"245","NF043050","McLaughlin ME, Kruger GM, Slocum KL, et al.  2007.  The Nf2 tumor suppressor regulates cell-cell adhesion during tissue fusion.  PNAS 104: 3261-3266."
"246","NF043050","Kalamarides M, Stemmer-Rachamimov AO, Takahashi M, et al.  2008.  Natural history of meningioma development in mice reveals a synergy in Nf2 and p16Ink4a mutations.  Brain Pathol 18:62-70."
"247","NF043050","Diaz-Flores E and Shannon K.  2008.  Targeting oncogenic Ras.  Genes Dev 21:1989-1992."
"248","NF043050","Farassati F, Pan W, Yamoutour F, et al.  2008.  Ras signaling influences permissiveness of malignant peripheral nerve sheath tumor cells to oncolytic herpes.  Am J Pathol 173(6):1861-1872."
"249","NF043050","Kwon CH, Zhao D, Chen J, et al.  2008.  Pten haploinsufficiency accelerates formation of high grade astrocytomas.  Cancer Res 68(9):3286-3294."
"250","NF043050","Lush ME, Li Y, Kwon CH, et al.  2008.  Neurofibromin is required for barrel formation in the mouse somatosensory cortex.  J Neurosci 28(7):1580-1587."
"251","NF043050","Alcantara Llaguno SR, Chen J, and Parada LF.  2009.  Signaling in malignant astrocytomas: Role of neural stem calls and its therapeutic implications.  Clin Cancer Res 15(23):7124-9."
"252","NF043050","Morris ZS and McClatchey AI.  2009.  The neurofibroma cell of origin: SKPs expand the playing field.  Cell Stem Cell 4(5):371-372."
"253","NF043050","Alcantara Llaguno S, Chen J, Kwon CH, et al.  2009.  Malignant astrocytomas originate from neural stem/progenitor cells in a somatic tumor suppressor mouse model.  Cancer Cell 15(1):45-56."
"254","NF043050","
Lallemand D, Lampin A, and Giovannini M.  2009.  Tumor suppression functions of merlin are independent of its role as an organizer of Schwann cell actin cytoskeleton.  J Cell Sci 122(Pt 22):4141-4149.
"
"255","NF043050","Lallemand D, Manent J, Couvelard A, et al.  2009.  Merlin regulates transmembrane receptor accumulation and signaling at the plasma membrane in primary mouse Schwann cells and in human schwannomas.  Oncogene 28(6):854-865."
"256","NF043050","Lauchle JO, Kim D, Le DT, et al.  2009.  Response and resistance to MEK inhibition in leukemias initiated by hyperactive Ras.  Nature 461:411-414."
"257","NF043050","Lin L, Chen J, Richardson JA, et al.  2009.  Mice lacking neurofibromin develop gastric hyperplasia.  Am J Physiol Gastrointest Liver Physiol 297(4):G751-G761."
"258","NF043050","Curto M and McClatchey AI.  2008.  Nf2/Merlin: A coordinator of receptor signaling and intercellular contact.  Br J Cancer 98(2):256-262."
"259","NF043050","Alcantara Llaguno S, Chen J, Kwon C.-H, et al.  2008.  Neural and cancer stem cells in tumor suppressor mouse models of malignant astrocytoma.  Cold Spring Harb Symp Quant Biol 73:421-426."
"260","NF043050","Parrinello S, Noon LA, Harrisingh MC, et al.  2008.  NF1 loss disrupts Schwann cell-axonal interactions: A novel role for semaphorin 4F.  Genes Dev 22(23):3335-3348.

"
"261","NF043050","Yang FC, Ingram DA, Chen S, et al.  2008.  NF1-dependent tumors require a microenvironment containing Nf1+/- and c-kit dependent bone marrow.  Cell 135:437-448."
"262","NF043050","Schubbert S, Bollag G, and Shannon K.  2007.  Deregulated Ras signaling in developmental disorders: New tricks for an old dog.  Curr Opin Genet Develop 17:15-22."
"263","NF043050","Morris ZS and McClatchey AI.  2009.  Aberrant epithelial morphology and persistent EGFR signaling in a mouse model of renal cell carcinoma.  Proc Nat Acad Sci 106(24):976-982.

"
"264","NF043050","Yin B, Delwel R, Valk PJ, et al.  2009.  A retroviral mutagenesis screen reveals strong cooperation between Bcl11a overexpression and loss of the Nf1 tumor suppressor gene.  Blood 113:1075-1085."
"265","NF043107","Dilworth JT, Kraniak JM, Wojtkowiak JW, et al.  2006.  Molecular targets for emerging anti-tumor therapies for Neurofibromatosis Type 1.  Biochem Pharmacol 72:1485-92."
"266","NF043107","Wojtkowiak JW, Fouad F, LaLonde DT, et al, 2008. Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin. J Pharmacol Exp Ther. 326:1-11."
"267","NF043115","Mautner VF, Asuagbor FA, Dombi E, et al.  2008.  Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1.  Neuro Oncol 10(4):593-598."
"268","NF050009","Okada M, Wang Y, Jang S-W, et al.  2009.  Akt Phosphorylation of merlin enhances its binding to phosphatidylinositols and inhibits tumor suppressive activities of merlin.  Cancer Res 69(9):4043-4048."
"269","NF050012","Wilker EW, Yaffe MB, Stemmer-Rachamimov A, et al.  2008.  Validation of the p21-activated kinases as targets for inhibition in neurofibromatosis type 2.  Cancer Res 68(19):7932-7."
"270","NF050014","Farassati F, Pan W, Yamoutpour F, et al.  2008.  Ras signaling influences permissiveness of malignant peripheral nerve sheath tumor cells to oncolytic herpes.  Am J Pathol 173(6):1861-1872."
"271","NF050022","Higham CS, Steinberg SM, Dombi E, et al. 2017. SARC006: Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated Chemotherapy-Naive Malignant Peripheral Nerve Sheath Tumors. Sarcoma. Vol. 2017, Article ID 8685638, 8 pages."
"272","NF050028","Banerjee S, Byrd JN, Gianino SM, et al.  2010.  Neurofibromin controls cell growth by regulating STAT3 activity in vitro and in vivo.  Cancer Res 70:1356-1366."
"273","NF050028","Banerjee S, Gianino SM, Gao F, et al.  2011. Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically-engineered mouse model of Nf1-deficient astrocytes.  Mol Cancer Ther 10(2)279-291."
"274","NF050028","Hegedus B, Banerjee D, Yeh T-H, et al.  2008.  Preclinical cancer therapy in a mouse model of neurofibromatosis-1 optic glioma.  Cancer Res 68:240-249."
"275","NF050028","Banerjee D, Hegedus B, Gutmann DH, et al.  2007.  Detection and measurement of neurofibromatosis-1 mouse optic glioma in vivo.  Neuroimage 35:1434-1437."
"276","NF050030","Flaiz C, Chernoff J, Ammoun S, et al.  2009.  PAK kinase regulates Rac GTPase and is a potential target in human schwannomas.  Exp Neurology 218:137-144."
"277","NF050030","Deacon SW, Beeser A, Fukui JA, et al.  2008.  An isoform-selective, small-molecule inhibitor targets the autoregulatory mechanism of p21-activated kinase.  Chemistry & Biology 15(4):322-231."
"278","NF050041","Roth TM, Ramamurthy P, Muir D, et al.  2008.  Influence of hormones and hormone metabolites on the growth of Schwann cells derived from embryonic stem cells and tumor cell lines expressing variable levels of neurofibromin.  Dev Dyn 237:513-524."
"279","NF050041","Zheng H, Chang L, Patel N, et al.  2008.  Induction of abnormal proliferation by non-myelinating Schwann cells triggers neurofibroma formation.  Cancer Cell 13:117-128."
"280","NF050041","Joseph NM, Mosher JT, Buchstaller J, et al.  2008.  The loss of Nf1 transiently promotes self renewal but not tumorigenesis by neural crest stem cells.  Cancer Cell 13:129-140."
"281","NF050043","Bai Y, Liu YJ, Wang H, et al.  2007. Inhibition of the hyaluronan-CD44 interaction by merlin contributes to the tumor suppressor activity of merlin.  Oncogene 26:836-50."
"282","NF050043","Stamenkovic I and Yu Q.  2008.  CD44 meets merlin and ezrin:  Their interplay mediates the pro-tumor activity of CD44 and tumor-suppressing effect of merlin.  In:  Hyaluronan in Cancer Biology (Stern R, Ed.).  Elsevier Publishing, Amsterdam, The Netherlands."
"283","NF050043","Xu Y, Stamenkovic I, and Yu Q.  2010.  CD44 attenuates activation of the Hippo signaling pathway and is a prime therapeutic target for glioblastoma.  Cancer Res 70(6):2455-64."
"284","NF050043","Stamenkovic I and Yu Q.  2010.  Merlin, a 'magic' linker between the extracellular cues and intracellular signaling pathways that regulate cell motility, proliferation, and survival.  Curr Protein Pept Sci 11(6):471-484"
"285","NF050043","Stamenkovic I and Yu Q.  2009.  Shedding light on proteolytic cleavage of CD44: The responsible sheddase and functional significance of shedding.  J Invest Dermatol 129:1321-4."
"286","NF050050","Crotti TN, Walsh NC, Barnes GL, et al.  2006.  Neurofibromin expression in bone fracture healing.  J Bone Miner Res 21:S429."
"287","NF050061","Striedinger KS, VandenBerg SR, Baia GS, et al.  2008.   The neurofibromatosis 2 tumor suppressor gene product, merlin, regulates meningioma cell growth by signaling through YAP. Neoplasia 10:1204-112."
"288","NF050083","Dorsi M, Chen L, Murinson B, et al.  2008.  The tibial neuroma transposition (TNT) model of neuroma pain and hyperalgesia.  Pain 134(3):320-334."
"289","NF050130","Scheidenhelm DK, Pelletier CL, Weber JD, et al.  2007.  Mammalian target of rapamycin:master regulator of cell growth in the nervous system.  Histol Histopathol 22:895-903."
"290","NF050133","Stevenson DA, Viskochil DH, Schorry EK, et al.  2007. The use of anterolateral bowing of the lower leg in the diagnostic criteria for neurofibromatosis type 1.  Genet Med 9:409-412.

"
"291","NF050137","Bakal C, Aach J, Church G, Perrimon N. Quantitative Morphological Signatures Define Local Signaling Networks Regulating Cell Morphology. Science. 2007 Jun 22;316(5832):1753-6."
"292","NF050145","Demestre M, Herzberg J, Holtkamp N, et al. 2010.  Imatinib mesylate (Glivec) inhibits Schwann cell viability and reduces the size of human plexiform neurofibroma in a xenograft model. J. Neurooncol 98(1):11-19."
"293","NF050145","Holtkamp N, Malzer E, Zietsch J, et al.  2008.  EGFR and erbB2 in malignant peripheral nerve sheath tumors and implications for targeted therapy.  Neuro Oncol 10(6):946-957."
"294","NF050145","Demestre M, Messerli SM, Celli N, et al.  2009.  CAPE (caffeic acid phenethyl ester)-based propolis extract (Bio 30) suppresses the growth of human neurofibromatosis (NF) tumor xenografts in mice.  Phytother Res 23(2):226-230."
"295","NF050145","Holtkamp N, Okuducu AF, Mucha J, et al.  2006.  Mutation and expression of PDGFRA and KIT in malignant peripheral nerve sheath tumors, and its implications for imatinib sensitivity.  Carcinogenesis 7(3):664-671."
"296","NF050153","Acosta MT, Kardel PG, Walsh KS, et al.  2011.  Lovastatin as treatment for neurocognitive deficits in NF1: Phase I study.  Pediatr Neurol 45(4):241-5."
"297","NF050153","Chabernaud C, Mennes M, Kardel PG, et al.  2012.  Lovastatin regulates brain spontaneous low-frequency brain activity in neurofibromatosis type 1.  Neurosci Lett 515(1):28-33."
"298","NF050171","Kielland A, Bochorishvili G, Corson J, et al.  2009.  Activity patterns govern synapse-specific AMPA-R trafficking between deliverable and synaptic pools.  Neuron 62:84-101."
"299","NF050171","Hu H, Qin Y, Bochorishvili G, et al.  2008.  Ras signaling mechanisms underlying impaired GluR1-dependent plasticity associated with fragile X syndrome.  J Neurosci 28:7847-7862."
"300","NF050171","Stornetta RL and Zhu JJ.  2011.  Ras and Rap signaling in synaptic plasticity and mental disorders.  Neuroscientist 17(1):54-78.

"
"301","NF050175","Lee JS, Padmanabhan A, Shin J, et al.  2010.  Oligodendrocyte progenitor cell numbers and migration are regulated by the zebrafish orthologs of the NF1 tumor suppressor gene.  Hum Mol Genet 19:4643-4653."
"302","NF050175","Padmanabhan A, Lee JS, Ismat FA, et al.  2009.  Cardiac and vascular functions of the zebrafish orthologues of the type I neurofibromatosis gene NFI.  Proc Natl Acad Sci U S A 106(52):22305-22310."
"303","NF050175","Zhu C, Smith T, McNulty J, et al.  2011.  Evaluation and application of modularly assembled zinc-finger nucleases in zebrafish.  Development 138(20):4555-4564.


"
"304","NF050175","Shin J, Padmanabhan A, de Groh ED, et al. 2012. Zebrafish neurofibromatosis type 1 genes have redundant functions in tumorigenesis and embryonic development.  Dis Model Mech 5(6):881-894."
"305","NF050176","Sandsmark DK, Pelletier C, Weber JD, et al.  2007.  Mammalian target of rapamycin:  Master regulator of cell growth in the nervous system.  Histol Histopathol 22:895-903."
"306","NF050176","Sandsmark DK, Zhang H, Hegedus B, et al.  2007.  Nucleophosmin mediates mammalian target of rapamycin-dependent actin cytoskeleton dynamics and proliferation in neurofibromin-deficient astrocytes.  Cancer Res 67:4790-4799."
"307","NF050184","Ling J and Hoffman AR.  2011.  Associated chromosome trap for identifying long-range DNA interactions.  J Vis Exp 23(50)."
"308","NF050184","Ling JQ, Hou A, and Hoffman AR.  2011.  Long-range DNA interactions are specifically altered by locked nucleic acid-targeting of a CTCF binding site.  Biochim Biophys Acta 1809:24-33.

"
"309","NF050184","Ling J and Hoffman AR.  2007.  Epigenetics of long-range chromatin interactions.  Pediatr Res 61:11R-16R."
"310","NF050193","Hansen MR, Clark JJ, Gantz BJ, et al.  2008.  Effects of ErbB2 signaling on the response of vestibular schwannoma cells to gamma-irradiation.  Laryngoscope 118(6):1023-1030."
"311","NF050193","Brown KD and Hansen MR.  2008.  Lipid raft localization of erbB2 in vestibular schwannoma and Schwann cells.  Otol Neurotol 29(1):79-85."
"312","NF050193","Clark JJ, Provenzano M, Diggelmann HR, et al.  2008.  The ErbB inhibitors, trastuzumab and erlotinib, inhibit growth of vestibular schwannoma xenografts in nude mice: A preliminary study.  Otol Neurotol 29(6):846-853.

"
"313","NF050193","Cioffi JA, Yue WY, Mendolia-Loffredo S, et al.  2010.  MicroRNA-21 over-expression contributes to vestibular schwannoma cell proliferation and survival.  Otol Neurotol 31(9):1455-1462.

"
"314","NF050193","Yue WY Clark JJ, Domann F, et al.  2011.  Persistent C-Jun N-terminal kinase activity contributes to the survival of human vestibular schwannoma cells by suppressing accumulation of mitochondrial superoxides.  Neuro-Oncology 13(9):961-973."
"315","NF050193","Cioffi JA, Yue WY, Mendolia-Loffredo S, et al.  2010.  MicroRNA-21 over-expression contributes to vestibular schwannoma cell proliferation and survival.  Otol Neuroto. 31(9):1455-1462."
"316","NF050193","Woodson EA, Dempewolf R, Hansen MR, et al.  2010.  Long-term hearing results after microsurgery.  Otol Neurotol 31(7):1144-1152."
"317","NF050193","Provenzano M, Minner SA, Zander K, et al.  2011.  p75NTR expression and nuclear localization of p75NTR intracellular domain in spiral ganglion Schwann cells following deafness correlates with cell proliferation.  Mol Cell Neurosci 47(4):306-315."
"318","NF050202","Smith MJ, Esparza S, Merker VL, et al.  2013.  Plasma S100-beta is not a useful biomarker for tumor burden in neurofibromatosis.  Clin Biochem 46(7-8):698-700."
"319","NF050202","Plotkin SR, Bredella MA, Cai W, et al.  2012.  Quantitative assessment of whole-body tumor burden in adult patients with neurofibromatosis.  PLoS One 7(4):e35711."
"320","NF050202","Jaremko JL, MacMahon PJ, Torriani M, et al.  2012.  Whole-body MRI in neurofibromatosis: Incidental findings and prevalence of scoliosis.  Skeletal Radiol 41(8):917-923."
"321","NF060016","Weiss B, Widemann BC, Wolters P,  et al.  2015.  Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a neurofibromatosis Clinical Trials Consortium phase II study. Neuro Oncol 17(4):596-603."
"322","NF060016","Gutmann DH, Blakeley JO, Korf BR,  et al.  2013.  Optimizing biologically targeted clinical trials for neurofibromatosis. Expert Opin Investig Drugs 22(4):443-462."
"323","NF060016","Weiss B, Widemann BC, Wolters P, Dombi E, Vinks AA, Cantor A, Korf B, Perentesis J, Gutmann DH, Schorry E, Packer R, Fisher MJ.  Sirolimus for non-progressive NF1-associated plexiform neurofibromas: an NF clinical trials consortium phase II study. Pediatr Blood Cancer. 2014 Jun;61(6):982-6. PMID: 24851266"
"324","NF060016","Emoto C, Fukuda T, Mizuno T, Cox S, Schniedewind B, Christians U, Widemann BC, Fisher MJ, Weiss B, Perentesis J, Vinks AA. Age-dependent changes in sirolimus metabolite formation in patients with neurofibromatosis type 1. Ther Drug Monit. 2015 Jun;37(3):395-9."
"325","NF060016","Scott JR, Courter JD, Saldaña SN, Widemann BC, Fisher M, Weiss B, Perentesis J, Vinks AA. Population pharmacokinetics of sirolimus in pediatric patients with neurofibromatosis type 1. Ther Drug Monit. 2013 Jun;35(3):332-7."
"326","NF060049","Demestre M, Herzberg J, Holtkamp N, et al.  2010.  Imatinib mesylate (Gleevec) inhibits Schwann cell viability and reduces the size of human plexiform neurofibroma in a xenograft model.  J Neurooncol 98:11-19."
"327","NF060049","Kanai R, Wakimoto H, Cheema T, et al.  2010.  Oncolytic herpes simplex virus vectors and chemotherapy: Are combinatorial strategies more effective for cancer?  Future Oncol 6:619-634."
"328","NF060049","Spyra M, Kluwe L, Hagel C, et al.  2011.  Cancer stem cell-like cells derived from malignant peripheral nerve sheath tumors.  PLoS ONE 6:e21099."
"329","NF060060","Ford B, Boykevisch S, Zhao C, et al.  2009.  Characterization of a Ras mutant with identical GDP- and GTP-bound structures.  Biochemistry 48:11449-11457."
"330","NF060060","Carpino N, Chen Y, Nassar N, et al.  2009.  The Sts proteins target tyrosine phosphorylated, ubiquitinated proteins within TCR signaling pathways.  J Immuno 46:3224-3231."
"331","NF060060","Nassar N, Singh K and Garcia-Diaz M.  2010.  Structure of the dominant negative S17N mutant of Ras.  Biochemistry 49(9):1970-4."
"332","NF060060","Chen Y, Jakoncic J, Keller J, et al.  2008.  Structural and functional characterization of the C-terminal domain of the ecdysteroid phosphate phosphatase from Bombix mori.  Biochemistry 47:12135-12145.

"
"333","NF060060","Chen Y, Jakoncic J, Carpino N, et al.  2009.  Structural and functional characterization of the 2H-phosphatase domain of Sts-2 reveals an acid-dependent phosphatase activity.  Biochemistry 48:1681-1690."
"334","NF060083","Hinman MN and Lou H.  2008.  Diverse molecular functions of Hu proteins.  Cell Mol Life Sci 65:3168-81."
"335","NF060083","Zhou HL, Hinman MN, Barron VA, et al.  2011.  Hu proteins regulate alternative splicing by inducing localized histone hyperacetylation in an RNAdependent manner.  Proc Natl Acad Sci U S A 108(36):E627-635."
"336","NF060094","Shilyansky C, Li W, Legius E, et al.  2008 (in press).  Molecular and cellular mechanisms of learning disabilities: a focus on neurofibromatosis type I.  In: Animal and Translational Models of Behavioral Disorders, Vol. 2 (McArthur RA and Borsini F, Eds.).  Elsevier, Amsterdam, The Netherlands."
"337","NF060121","Schlisio S, Kenchappa RS, Vredeveld LC, et al.  2008.  The kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor.  Genes Dev Apr 1;22(7):884-893."
"338","NF073102","McGillicuddy LT, Beroukhim R, Fromm JA, et al.  2009.  Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis.  Cancer Cell 16(1):44-54.  Also, highlighted in Nat Rev Cancer 9:610-611."
"339","NF073102","Hollstein PE and Cichowski K.  2013.  Identifying the ubiquitin ligase complex that regulates the NF1 tumor suppressor and Ras.  Cancer Discov 3(8):880-893."
"340","NF073102","McGillicuddy LT, Beroukhim R, Fromm JA, et al.  2009.  Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis.  Cancer Cell 16(1):44-54.

"
"341","NF073112","Xiaohua W., Chen S., He Y, et al. 2011. The Haploinsufficient Hematopoietic Microenvironment is Critical to the Pathological Fracture Repair in Murine Models of Neurofibromatosis Type 1. PLoS ONE 6(9): e24917. 
"
"342","NF073112","Sharma R, Wu X, Rhodes SD, et al.  2013.  Hyperactive Ras/MAPK signaling is critical for tibial nonunion fracture in neurofibromin-deficient mice.  Hum Mol Genet 22(23):4818-4828."
"343","NF073122","Lasater EA, Li F, Bessler WK, et al.  2010.  Genetic and cellular evidence of vascular inflammation in neurofibromin deficient mice and humans.  J Clin Invest 120(3):859-870."
"344","NF073122","Lasater BA, Bessler WK, Mead LE, et al.  2008.  Nfl +/mice have increased neointima formation via hyperactivation of a Gleevec sensitive molecular pathway.  Hum Mol Genet 17(15):2336-2344.  "
"345","NF073146","Whitsell L and Linquist S.  2009.  Inhibiting the transcription factor HSF1 as an anticancer strategy.  Expt Opin Ther Targets 13:469-478."
"346","NF073146","Dai C, Santagata S, Tang Z, et al.  2012.  Loss of tumor suppressor NF1 activates HSF1 to promote carcinogenesis.  J Clin Invest 122(10):3742-3754."
"347","NF080017","Ye Y, McDevitt MA, Guo M, et al.  2009.  Progressive chromatin repression and promoter methylation of CTNNA1 is associated with AML transformation.  Cancer Res 69(21):8482-8490.
"
"348","NF080017","Hiroi T, Deming CB, Zhao H, et al.  2009.  Proteasome inhibitors augment endothelial thromboresistance via induction of Kruppel-like transcription factors.  Atheroscler Thromb Vasc Biol 29(10):1587-1593.
"
"349","NF080017","Tiu RV, Gondek LP, Oâ¿¿Keefe C, et al.  2009.  New lesions detected by single nucleotide polymorphism array-based chromosomal analysis have important clinical impact in acute myeloid leukemia.  J Clin Oncol 27(31):5219-5226.
"
"350","NF080017","Makishima H, Tiu RV, Cazolli H, et al.  2009.  Mutations of E3 ubiquitin ligase CBL family members constitute a novel common pathogenic lesion in myeloid malignancies.  J of Clin Oncol 27(36):6109-6116.
"
"351","NF080017","Wang W, Nyman JS, Stevenson DA, et al.  2011.  Mice lacking Nf1 in osteochondroprogenitor cells display skeletal dysplasiae similar to patients with neurofibromatosis type I.  Human Mol Gen 20:3910-3924."
"352","NF080017","Jasek M, Gondek LP, Bejanyan N, et al.  2010.  TP53 mutations in myeloid malignancies are either homozygous or hemizygous due to copy number-neutral loss of heterozygosity or deletion of 17p. Leukemia. 24(1):216-9."
"353","NF080041","Saydam O, Senol O, Würdinger T, et al.  2011.  miRNA-7 attenuation in Schwannoma tumors stimulates growth by upregulating three oncogenic signaling pathways.  Cancer Res 71(3):852-861."
"354","NF080045","Bajaj A, Li Q-F, Zheng Q, et al.  2012.  Loss of NF1 expression in human endothelial cells promotes autonomous proliferation and altered vascular morphogenesis.  PLOS One 7(11):e49222."
"355","NF080062","Yin Z, Pringle DR, Jones GN, et al.  2011.  Differential role of PKA catalytic subunits in mediating phenotypes caused by knockout of the Carney complex gene Prkar1a.  Mol Endocrinol 25:1786-1793."
"356","NF080062","Manchanda PK, Jones GN, and Lee AA.  2013.  Rac1 is required for Prkar1a-mediated Nf2 suppression in Schwann cell tumors.  Oncogene 32:3491-3499."
"357","NF080075","Longworth MS, Walker JA, Anderssen E, et al.  2012.  A shared role for RBF1 and dCAP-D3 in the regulation of transcription with consequences for innate immunity.  GLos Genet 8(4):e1002618."
"358","NF080075","Stefano LD, Walker JA, Burgio G, et al.  2011.  Functional antagonism between histone H3K4 demethlyases in vivo.  Genes Dev 25:17-28."
"359","NF080075","Smith MJ, Walker JA, Shen Y, et al.  2012.  cDNA analysis of SMARCB1 (INI1) mutations in familial and sporadic schwannomatosis.  Hum Mol Genet 21(24):5239-5245."
"360","NF080075","Miles WO, Dyson NJ, and Walker JA.  2011.  Modeling tumor invasion and metastasis in Drosophila.  Dis Model Mech 4(6):753-761."
"361","NF080082","Hodgdon KE, Hingtgen CM, and Nicol GD.  2012.  Dorsal root ganglia isolated from Nf1+/- mice exhibit increased levels of mRNA expression of voltage-dependent sodium channels.  Neuroscience 206:237-244."
"362","NF080089","Brossier NM and Carroll SL.  2012.  Genetically engineered mouse models shed new light on the pathogenesis of neurofibromatosis type 1-related neoplasms of the peripheral nervous system.  Brain Res Bull 88: 58-71. "
"363","NF080089","Carroll SL.  2012.  Molecular mechanisms promoting the pathogenesis of Schwann cell neoplasms.  Acta Neuropathol 123(3): 321-328. "
"364","NF080089","Turk AN, Byer SJ, Zinn KR et al.  2011.  Orthotopic xenografting of human luciferase-tagged malignant peripheral nerve sheath tumor cells for in vivo testing of candidate therapeutic agents.  J Vis Exp (49). pii:2558."
"365","NF080089","Brossier NM, Byer SJ, Peavler LT, et al.  2011.  ErbB membrane tyrosine kinase receptors: Analyzing migration in a highly comples signaling system.  In: Neuromethods ¿ Protein Kinase Technologies (Walz W, Ed.), Springer Protocols - Humana Press, New York."
"366","NF080089","Byer SJ, Eckert JM, Brossier NM, et al. 2011.  Tamoxifen inhibits malignant peripheral nerve sheath tumor growth in an estrogen receptor-independent manner.  Neuro Oncol 13(1):28-41."
"367","NF080089","Kohli L, Lavalley N, Kaza N, et al.  2012.  The pan erbB inhibitor PD168393 enhances lysosomal dysfunction-induced apoptotic death in MPNST cells.  Neuro Oncol 14(3): 266-277."
"368","NF093033","Brown JA, Xu J, Diggs-Andrews KA, et al.  2011.  PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.  Exp Neurol 232(2):333-338."
"369","NF093033","Gutmann DH, Parada LF, Silva AJ, et al.  2012.  Neurofibromatosis type 1: Modeling CNS dysfunction.  J Neurosci 32(41):14087-14093."
"370","NF093033","Diggs-Andrews KA and Gutmann DH.  2013.  Modeling cognitive dysfunction in neurofibromatosis-1.  Trends Neurosci 36:237-247."
"371","NF093033","Diggs-Andrews KA, Tokuda K, Izumu Y, et al.  2013.  Dopamine deficiency underlies learning deficits in Neurofibromatosis-1 mice.  Ann Neurol 73:309-315."
"372","NF093033","Wozniak DF, Diggs-Andrews KA, Conyers S, et al.  2013.  Motivational disturbances and effects of L-dopa administration in neurofibromatosis-1 model mice.  PLoS One 8:e66024."
"373","NF093047","Ramos A and Camargo FD.  2012.  Hippo signaling pathway and stem cell biology.  Trends Cell Biol 22(7):339-346."
"374","NF093047","Tremblay AM, and Camargo FD.  2012.  Hippo signaling in mammalian stem cells.  Semin Cell Dev Biol 23(7):818-826."
"375","NF093047","Mohseni M, Sun J, Lau A, et al.  2014.  A genetic screen identifies an LKB1¿MARK signaling axis controlling the Hippo-YAP pathway.  Nat Cell Biol 16(1):108-117.

"
"376","NF093047","Yimlamai D, Christodoulou C, Galli GG, et al.  2014.  Hippo pathway activity influences liver cell fate.  Cell 157(6):1324-1338."
"377","NF093047","Mori M, Triboulet R, Mohensi M, et al.  2014.  Hippo signaling regulates microprocessor and links cell-density-dependent miRNA biogenesis to cancer.  Cell 156(5):893-906."
"378","NF093053","Kalamarides M, Acosta M, Babovic-Vuksanovic D, et al.  2012.  Neurofibromatosis 2011:  A Report of the Children's Tumor Foundation Annual Meeting.  Acta Neuropathol 123(3):369-380. 

"
"379","NF093053","Mayes DA, Rizvi TA, Cancelas JA, et al.  2011.  Perinatal or adult Nf1 inactivation using tamoxifen-inducible PlpCre each cause neurofibroma formation.  Cancer Res 71(13):4675-4685."
"380","NF093059","Lee S, Cimica V, Ramachandra N, et al.  2011.  Aurora A is a repressed effector target of the chromatin remodeling protein INI1/hSNF5 required for rhabdoid tumor cell survival.  Cancer Res 71(9):3225-3235."
"381","NF093059","Plotkin SR, Blakeley JO, Evans DG, et al.  2013.  Update from the 2011 International Schwannomatosis Workshop: From genetics to diagnostic crieria.  Am  Med Geneet Part A 161A405-416."
"382","NF093068","Lee MH, Lin SR, Chang JY, et al.  2010.  TGF-beta induces TIAF1 self-aggregation via type II receptor-independent signaling that leads to generation of amyloid beta plaques in Alzheimer¿s disease.  Cell Death Dis 1, e110."
"383","NF093068","Subhan D, Huang SS, Hong Q, et al.  2010.  Zfra is a small wizard in the mitochondrial pathway of apoptosis.  Aging 2:1023-1029."
"384","NF093068","Lin HP, Chang JY, Huang SS, et al.  2011.  Phorbol ester dissociates an in vivo MEK/WOX1 complex for switching on a novel type of apoptosis in T lymphocytes.  Genes Cancer 2(5):550-562."
"385","NF093068","Chang JY, Chiang MF, Lin SR, et al.  2012.  TIAF1 self-aggregation in peritumor capsule formation, spontaneous activation of SMAD-responsive promoter in p53-deficient environment, and cell death.  Cell Death Disease 3:e302."
"386","NF093077","Sarver A and Subramanian S.  2012.  Competitive endogenous RNA database.  Bioinformation 8(15):731-733."
"387","NF093077","Subramanian S and Kartha RV.  2012.  MicroRNA mediated gene regulations in human sarcomas.  Cell Mol Life Sci 69(21):3571-3585."
"388","NF093077","Shu J, Xia Z, Li L, et al.  2012.  Dose-dependent differential mRNA target selection and regulation by let-7a-7f and miR-17-92 cluster microRNAs.  RNA Biol 9:1275-1287."
"389","NF093079","Boggiano JC, Vanderzalm PJ, and Fehon RG.  2011.  Tao-1 phosphorylates Hippo/MST kinases to regulate the Hippo-Salvador-Warts tumor suppressor pathway.  Dev Cell 21(5):888-895."
"390","NF093089","Yogesha S, Sharff A, Giovannini M, et al.  2011.  Unfurling of the band 4.1, erzin, radixin, moesin (FERM) domain of the merlin tumor suppressor.  Protein Science 20:2113-2120."
"391","NF093091","Vitte J, Gao F, Coppola G, et al.  2017.  Timing of Smarcb1 and Nf2 inactivation determines schwannoma versus rhabdoid tumor development.  Nat Commun 8(1):300."
"392","NF093118","Chow HY, Stepanova D, Koch J, et al.  2010.  p21-activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.  PLos ONE 5(11):e13791."
"393","NF093135","Shuai YC, Hu Y, Qin H, Campbell RA, et al.  2011.   Distinct molecular underpinnings of Drosophila olfactory trace conditioning.   Proc Nat Acad Sci USA 108:20201-20206."
"394","NF093145","Zhang N, Bai H, David KK, et al.  2010.  The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals.  Dev Cell 19:27-38."
"395","NF093145","Pan D.  2010.  The Hippo signaling pathway in development and cancer.  Dev Cell 19:491-505."
"396","NF093145","Yin F, Yu J, Zheng Y, et al.  2013.  Spatial organizational of hippo signaling at the plasma membrane mediated by the tumor suppressor Merli/NF2.  Cell 154:1342-1355."
"397","NF100047","James MF, Stivison E, Beauchamp R, et al.  2012.  Regulation of mTOR complex 2 signaling in NF2-deficient target cell types.  Mol Cancer Res 10:649-659.

"
"398","NF100047","Beauchamp RL, James MF, DeSouza PA, et al.  2015.  A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.  Oncotarget 6(19):16981-16997."
"399","NF100053","Wu J, Patmore DM, Jousma E, et al.  2014  EGFR-STAT3 signaling promotes formation of malignant peripheral nerve sheath tumors.  Oncogene 33:173-180."
"400","NF100057","Plotkin SR and Albers AC.  2014.  Update from the 2013 International Neurofibromatosis Conference.  Am J Med Genet A 164A:2969-2978."
"401","NF100057","Paria N and Cho TJ.  2014.  Neurofibromin deficiency associated transcription dysregulation suggests a novel therapy for tibial pseudoarthrosis in NF1.  J Bone Miner Res 29(12):2636-2642."
"402","NF100082","De Raedt T, Beert E, Pasmant E, et al.  2014.  PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies.  Nature 514(7521):247-251."
"403","NF100085","Mo W, Chen J, Patel A, et al.  2013.  CXCR4/CXCL12 mediate autocrine cell-cycle progression in NF1-associated malignant peripheral nerve sheath tumors.  Cell 152(5):1077-1090."
"404","NF100087","Sharma R, Wu X, Rhodes SD, et al.  2013.  Hyperactive Ras/MAPK signaling is critical for tibial nonunion fracture in neurofibromin-deficient mice.  Hum Mol Genet 22(23):4818-4828."
"405","NF100087","He Y, Rhodes SD, Chen S, et al.  2012.  c-Fms signaling mediates neurofibromatosis Type-1 osteoclast gain-in-functions.  PLoS One 7(11):e46900."
"406","NF100087","Rhodes S, Wu X, He Y, et al.  2013.  Hyperactive transforming growth factor-beta1 signaling potentiates skeletal defects in a neurofibromatosis type 1 mouse model.  J Bone Miner Res 28(12):2476-2489."
"407","NF100087","Wu X, Chen S, He Y, et al.  2011.  The haploinsufficient hematopoietic microenvironment is sufficient to normalize the pathological fracture repair in genetically engineered murine models of neurofibromatosis type 1.  PLoS One 6(9):e24917."
"408","NF100090","Baia GS, Caballero OL, Orr BA, et al.  2012.  Yes-associated protein 1 is activated and functions as an oncogene in meningiomas.  Mol Cancer Res 10(7):904-913."
"409","NF100090","Baia GS, Caballero OL, and Riggins GJ.  2012.  The Hippo signaling pathway and translational opportunities for brain cancers.  CNS Oncology 1(2):113-115."
"410","NF100099","Moutal A, Wang Y, Yang X, et al. 2017. Dissecting the role of the CRMP2-Neurofibromin complex on pain behaviors. Pain 11:2203-2221. doi: 10.1097/j.pain.0000000000001026."
"411","NF100099","Moutal A, Sun L, Yang X, Li W, Cai S, Luo S, Khanna R. CRMP2-Neurofibromin Interface Drives NF1-related Pain. Neuroscience. 2018 Jun 15;381:79-90. doi: 10.1016/j.neuroscience.2018.04.002. Epub 2018 Apr 12. PubMed PMID: 29655575."
"412","NF100099","Moutal A, Yang X, Li W, et al. 2017. CRISPR/Cas9 editing of Nf1 gene identifies CRMP2 as a therapeutic target in neurofibromatosis type 1 (NF1)-related pain that is reversed by (S)-Lacosamide.  Pain 158(12):2301-2319. doi: 10.1097/j.pain.0000000000001002."
"413","NF100099","Wilson SM, Schmutzler BS, Brittain JM, et al.  2012.  Inhibition of transmitter release and attenuation of AIDS therapy induced and tibial nerve injury-related painful peripheral neuropathy by novel synthetic Ca2+ channel peptides.  J Biol Chem 287(42):35065-35077."
"414","NF100099","Ju W, Li Q, Wilson SM, et al.  2013.  SUMOylation alters CRMP2 regulation of calcium influx in sensory neurons.  Channels (Austin) 7(3):153-159."
"415","NF100099","Quach TT, Wilson SM, Rogemond V, et al.  2013.  Mapping CRMP3 domains involved in dendrite morphogenesis and voltage-gated calcium channel regulation.  J Cell Science 126(Pt 18):4262-4273."
"416","NF100099","Khanna R, Wilson SM, Brittain JM, et al.  2012.  Opening Pandora¿s Jar: A primer on the putative roles of collapsin response mediator protein 2 (CRMP2) in a panoply of neurodegenerative, sensory and motor neuron, and central disorders.  Future Neurol 7(6):749-771."
"417","NF100136","Tan M, Zhao Y, Kim SJ,et al.  2011.  SAG/RBX2/ROC2 E3 ubiquitin ligase is essential for vascular and neural development by targeting NF1 for degradation.  Developmental Cell 21(6):1062-1076."
"418","NF100136","Wang Y, Kim E, Wang X, et al.  2012.  ERK inhibition rescues fate-specification defects of Nf1-deficient neural progenitors and brain abnormalities.  Cell 150(4):816-830."
"419","NF110047","Chen Z, Pradhan S, Liu C, et al.  2012.  Skin-derived precursors as a source of progenitors for cutaneous nerve regeneration.  Stem Cells 30(10):2261-2270."
"420","NF110047","Mo W, Chen J, Patel A, et al.  2013.  CXCR4/CXCL12 mediate autocrine cell cycle progression in NF1-associated malignant peripheral nerve sheath tumors.  Cell 152(5):1077-1090."
"421","NF110047","Chen Z, Liu C, Patel A, et al.  2014.  Cells of origin in the embryonic nerve roots for NF1-associated plexiform neurofibromas.  Cancer Cell 26(5):695-706."
"422","NF110047","Patel A, Liao CP, Chen Z, et al.  2014.  Bromodomain inhibition triggers apoptosis of NF1-associated malignant peripheral nerve sheath tumors through Bim induction.  Cell Rep 6(1):81-92."
"423","NF110052","Packer RJ, Fisher MJ, Cutter G, et al. 2018. Neurofibromatosis Clinical Trial Consortium. J Child Neurol 33(1): 82-91. doi: 10.1177/0883073817739196."
"424","NF110057","Choi K, Komurov K, Fletcher JS, Jousma E, Cancelas JA, Wu J, Ratner N. An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system. Sci Rep. 2017 Mar 3;7:43315. doi: 10.1038/srep43315. PubMed PMID: 28256556; PubMed Central PMCID: PMC5335359."
"425","NF110080","Jonas RK, Roh E, Montojo CA, et al. 2017. Risky decision making in Neurofibromatosis Type 1: An exploratory study. Biol Psychiatry Cogn Neurosci Neuroimaging 2(2):170-179. doi: 10.1016/j.bpsc.2016.12.003.PMID: 28736755 PMCID: PMC5518467."
"426","NF110080","Tomson SN, Schreiner M, Narayan M, et al.  2015. Resting state functional MRI reveals abnormal network connectivity in Neurofibromatosis 1.  Hum Brain Mapp 36(11):4566-4581."
"427","NF110082","Brosius SN, Turk AN, Byer SJ, et al.  2014.  Neuregulin-1 overexpression and Trp53 haploinsufficiency cooperatively promote de novo malignant peripheral nerve sheath tumor pathogenesis.  Acta Neuropath 127(4):573-591."
"428","NF110082","Brossier NM, Prechtl AM, Longo JF, et al.  2015.  Classic Ras proteins promote proliferation and survival via distinct phosphoproteome alterations
in neurofibromin-null malignant peripheral nerve sheath tumor cells. J Neuropath Experimental Neuro 74(6):568-586."
"429","NF110082","Hanemann CO, Blakeley JO, Nunes FP, et al.  2016.  Current status and recommendations for biomarkers in neurofibromatosis.  Neurology, 87(7 Supplement 1): S40-48."
"430","NF110082","Brosius SN, Turk AN, Byer SJ, et al.  2014.  Combinatorial therapy with tamoxifen and trifluoperazine effectively inhibits malignant peripheral nerve sheath tumor growth by targeting complementary signaling cascades.  J Neuropathol Experiment Neurol 73(11): 1078-1090."
"431","NF110082","Kaza N, Kohli L, Graham CD, et al.  2014.  BNIP3 regulates AT101 [(-)-gossypol] induced malignant peripheral nerve sheath tumor cell death.  PLoS One 9(5):e96733."
"432","NF110082","Carroll SL. 2016.  The challenge of cancer genomics in rare nervous system neoplasms: malignant peripheral nerve sheath tumors as a paradigm for cross-species comparative oncogenomics.  American J Pathol 186(3):464-477."
"433","NF110082","Kazmi SJ, Byer SJ, Eckert JM, et al.  2013.  Transgenic mice overexpressing neuregulin-1 model neurofibromamalignant peripheral nerve sheath tumor progression and implicate specific chromosomal copy number variations in tumorigenesis.  Am J Pathol 182(3): 646-677."
"434","NF110091","Burgess MR, Hwang E, Firestone AJ, et al.  2014.  Preclinical efficacy of MEK inhibition in Nras mutant acute myeloid leukemia.  Blood 124:3947-3955."
"435","NF110103","Brastianos PK, Horowitz PM, Santagata S, et al.  2013.  Genomic sequencing of meningiomas reveals oncogenic SMO and AKT1 mutations.  Nature Genetics 45(3):285-289."
"436","NF110105","Brown K, Seol H, Pillai DK, et al.  2013.  The human secretome atlas initiative: implications in health and disease conditions.  Biochim Biophys Acta 1834(11):2454-2461."
"437","NF110105","Hathout Y.  2015.  Proteomic methods for biomarker discovery and validation. Are we there yet.  Expert Rev Proteomics 12(4):329-331."
"438","NF110108","Ki DH, He S, Rodig S, et al. 2017. Overexpression of PDGFRA cooperates with loss of NF1 and p53 to accelerate the molecular pathogenesis of malignant peripheral nerve sheath tumors.  Oncogene 36:1058-1068."
"439","NF110108","Zhu C, Smith T, McNulty J, et al.  2011.  Evaluation and application of modularly assembled zinc-finger nucleases in zebrafish.  Development 138(20):4555-4564."
"440","NF110108","Shin J, Padmanabhan A, de Groh E, et al.  2012.  Zebrafish neurofibromatosis type 1 genes have redundant functions in tumorigenesis and embryonic development.  Dis Model Mech 5(6):881-894."
"441","NF110108","Wolman MA, de Groh ED,  McBride SM, et al.  2014. Modulation of cAMP and Ras Signaling Pathways Improves Distinct Behavioral Deficits in a Zebrafish Model of Neurofibromatosis Type 1. Cell Rep 8(5):1265-1270."
"442","NF120032","Chen Y-H, McGowan LD, Cimino PJ, et al.  2015.  Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.  Cell Reports 10:1899-1912."
"443","NF120032","Hambardzumyan D, Gutmann DH, and Kettenmann H.  2016.  The role of microglia and macrophages in glioma maintenance and progression.  Nat Neurosci 19:20-27."
"444","NF120032","Gutmann DH.  2014.  Eliminating barriers to precision medicine:  learning from neurofibromatosis type 1.  Neurology 83(5):463-471."
"445","NF120070","Walker JA, and Bernards A. 2014.  A Drosophila screen identifies neurofibromatosis-1 genetic modifiers involved in systemic and synaptic growth. Rare Dis 2:e28341."
"446","NF120078","Joiakim A, Mathieu PA, Boerner J, et al.  2016.  Epidermal growth factor receptor kinase inhibitors synergize with TCDD to induce CYP1A1/1A2 in human breast epithelial MCF10A cells.  Drug Metab Dispos 44(5):655-671."
"447","NF120081","Weiss JB, Weber S, Marzulla T, et al. 2017. Pharmacological inhibition of Anaplastic Lymphoma Kinase rescues spatial memory impairments in Neurofibromatosis 1 mutant mice.  Behav Brain Res. 332:337-342 pii: S0166-4328(17)30814-8."
"448","NF120085","Malone CF, Fromm JA, Maertens O, et al.  2014.  Defining key signaling nodes and therapeutic biomarkers in NF1-mutant cancers.  Cancer Discov 4(9):1062-1073."
"449","NF120085","Lock R, Ingraham R, Maertens O, et al.  2016.  Cotargeting MNK and MEK kinases induces the regression of NF1-mutant cancers.  J Clin Invest 126(6):2181-2190."
"450","NF130029","Liao CP, Pradhan S, Chen Z, et al.  2016.  The roles of nerve microenvironment for neurofibroma development.  Oncotarget 7(38):61500-61508."
"451","NF130030","Xie K, Colgan LA, Dao MT, et al.  2016.  NF1 is a direct G protein effector essential for opioid signaling to Ras in the striatum.  Current Biology 26:2992-3003."
"452","NF130061","Reimels TA, and Pfleger CM.  2015.  Drosophila Rabex-5 restricts Notch activity in hematopoietic cells and maintains hematopoietic homeostasis.  J Cell Sci 128:4512-4525."
"453","NF130061","Fagan JK, Dollar G, Lu Q, et al.  2014.  Combover/CG10732, a novel PCP effector for Drosophila wing hair formation.  PLoS One 9(9):e107311."
"454","NF130064","Summers MA, Rupasinghe T, Vasiljevski ER, et al. 2018. Dietary intervention rescues myopathy associated with neurofibromatosis type 1. Hum Mol Genet 27(4): 577-588. doi: 10.1093/hmg/ddx423."
"455","NF130064","Summers MA, Quinlan KG, Payne JM, et al.  2015.  Skeletal muscle and motor deficits in Neurofibromatosis Type 1. J Musculoskelet Neuronal Interact 15(2):161-70."
"456","NF130071","Cohen MA, Wert KJ, Goldmann J, et al.  2016.  Human neural crest cells contribute to coat pigmentation in interspecies chimeras after in utero injection into mouse embryos.  Proc Natl Acad Sci U S A.  113(6):1570-1575."
"457","NF130072","Ahmad I, Fernando A, Gurgel R, et al.  2015.  Merlin status regulates p75NTR expression and apoptotic signaling in Schwann cells following nerve injury.  Neurobiol Dis 82:114-122."
"458","NF130072","Cheng E and Hansen MR.  2016.  Schwannomas provide insight into the role of p75NTR and merlin in Schwann cells following nerve injury and during regeneration.  Neural Regen Res 11(1):73-74."
"459","NF130101","Dodd RD, Lee CL, Overton T, et al. 2017. NF1 +/- hematopoietic cells accelerate malignant peripheral nerve sheath tumor development without altering chemotherapy response. Cancer Res 77(16):4486-4497. doi: 10.1158/0008-5472.CAN-16-2643."
"460","NF130108","Chow HY, Dong B, Duron SG, et al.  2015.  Group I Paks as therapeutic targets in NF2-deficient meningioma.  Oncotarget 6(4):1981-1994."
"461","NF130120","Dilwali S, Kao SY, Fujita T, et al.  2015.  Nonsteroidal anti-inflammatory medications are cytostatic against human vestibular schwannomas.  Transl Res 166(1):1-11."
"462","NF130120","Landegger LD, Sagers JE, Dilwali S, et al. 2017. A unified methodological framework for vestibular schwannoma research. J Vis Exp. 2017 Jun 20;(124) PMID: 28654042  DOI: 10.3791/55827."
"463","NF130120","Kandathil C, Cunnane ME, Curtin H, et al.  2016.  Correlation between aspirin intake and reduced growth of human vestibular schwannoma: Volumetric analysis.  Otology and Neurotology 37(9):1428-1434."
"464","NF130120","Kim BG, Fujita T, Stankovic KM, et al.  2016.  Sulforaphane, a natural component of broccoli, inhibits vestibular schwannoma growth in vitro and in vivo.  Sci Reports 6:36215."
"465","NF130120","Soares VYR, Atai NA, Fujita T, et al.  2016.  Extracellular vesicles derived from human vestibular schwannomas associated with poor hearing damage cochlear cells.  Neuro-Oncology 18(11):1498-1507."
"466","NF130120","Dilwali S, Roberts D, and Stankovic KM.  2015.  Interplay between VEGF-A and cMET signaling in human vestibular schwannomas and schwann cells.  Cancer Biol Ther.  16(1):170-175."
"467","NF130120","Dilwali KS, Landegger LD, Soares VYR, et al.  2015.  Secreted factors from human vestibular schwannomas can cause cochlear damage.  Scientific Reports 5:18599."
"468","NF140031","Zhang H, Hudson FZ, Xu Z, et al. 2018. Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization. Invest Ophthalmol Vis Sci. 59(6): 2520-2528. doi: 10.1167/iovs.17-22588."
"469","NF140031","Bessler WK, Hudson FZ, Wang Y, et al.  2016.  Neurofibromin is a novel regulator of Ras-induced reactive oxygen species production in mice and humans. Free Radic Biology Med (97):212-222."
"470","NF140031","Bessler WK, Kim G, Hudson FZ, et al.  2016.  Nf1+/- Monocytes/Macrophages induced neointima formation via CCR2 activation.  Hum Mol Genet 25(6):1129-1139."
"471","NF140044","Fuse MA, Dinh CT, Vitte J, Kirkpatrick J, Mindos T, Plati SK, Young JI, Huang J, Carlstedt A, Franco MC, Brnjos K, Nagamoto J, Petrilli AM, Copik AJ, Soulakova JN, Bracho O, Yan D, Mittal R, Shen R, Telischi FF, Morrison H, Giovannini M, Liu XZ, Chang LS, Fernandez-Valle C. Preclinical assessment of MEK1/2 inhibitors for neurofibromatosis type 2-associated schwannomas reveals differences in efficacy and drug resistance development. Neuro Oncol. 2019 Mar 18;21(4):486-497. doi: 10.1093/neuonc/noz002. PubMed PMID: 30615146; PubMed Central PMCID: PMC6422635."
"472","NF140062","Prieto-Granada CN, Wiesner T, Messina JL, et al.  2016.  Loss of H3K27me3 expression is a highly sensitive marker for sporadic and radiation-induced MPNST.  Am J Surg Patho 40:479-89."
"473","NF140082","Carroll S.  2016.  The challenge of cancer genomics in rare nervous system neoplasms: malignant peripheral nerve sheath tumors as a paradigm for cross-species comparative oncogenomics.  American J Pathology 186(3):464-477."
"474","NF140082","Hanemann CO, Blakeley JO, Nunes FP, et al.  2016.  Current status and recommendations for biomarkers and biobanking in neurofibromatosis.  Neurology 87(7) Supplement 1."
"475","NF150024","Wrobel MR, and Sundararaghavan HG.  2017.  Positive and negative cues for modulating neurite dynamics and receptor expression.  Biomed Mater 12(2): 025016."
"476","NF150024","Whitehead TJ, Avila CO, and Sundararaghavan HG. 2017. Combining growth factor releasing microspheres within aligned nanofibers enhances neurite outgrowth. J Biomed Mater Res A. 106(1):17-25. doi: 10.1002/jbm.a.36204. Epub 2017 Sep 23."
"477","NF150070","Brosseau JP, Liao CP, Wang Y, et al. NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation. Nature communications. 2018 11; 9(1): 5014. https://doi.org/10.1038/s41467-018-07452-y PMID:30479396"
"478","NF150076","Köhler M, Ehrenfeld S, Halbach S, Lauinger M, Burk U, Reischmann N, Cheng S, Spohr C, Uhl FM, Köhler N, et al. B-Raf deficiency impairs tumor initiation and progression in a murine breast cancer model. Oncogene. 2019 Feb;38(8):1324-1339. doi: 10.1038/s41388-018-0663-8. Epub 2019 Jan 18. PubMed PMID: 30659267."
"479","NF160027","Vranceanu AM, Zale EL, Funes CJ, Macklin EA, McCurley J, Park ER, Jordan JT, Lin A, Plotkin SR. Mind-Body Treatment for International English-Speaking Adults With Neurofibromatosis via Live Videoconferencing: Protocol for a Single-Blind Randomized Controlled Trial. JMIR Res Protoc. 2018 Oct 23;7(10):e11008. doi: 10.2196/11008. PubMed PMID: 30355560; PubMed Central PMCID: PMC6231775."
"480","NF960003","Szudek J, Evans DG, and Friedman JM.  2003.  Patterns of associations of clinical features in neurofibromatosis 1 (NF1).  Hum Genet 112: 289-297."
"481","NF960003","Friedman JM, Birch P (1997): An association between optic glioma and other tumours of the central nervous system in neurofibromatosis type 1. Neuropediatrics 28:131-2."
"482","NF960003","Szudek J, Friedman JM (2002): Unidentified bright objects associated with features of neurofibromatosis 1. Pediatr Neurol 27:123-7."
"483","NF960003","Rasmussen SA, Friedman JM (2000): NF1 gene and neurofibromatosis 1. American Journal of Epidemiology 151:33-40."
"484","NF960003","DeBella K, Poskitt K, Szudek J, Friedman JM (2000): Use of 'unidentified bright objects' on MRI for diagnosis of neurofibromatosis 1 in children. Neurology 54:1646-51."
"485","NF960003","DeBella K, Szudek J, Friedman JM (2000): Use of the national institutes of health criteria for diagnosis of neurofibromatosis 1 in children. Pediatrics 105:608-14."
"486","NF960003","Hamilton SJ, Friedman JM (2000): Insights into the pathogenesis of neurofibromatosis 1 vasculopathy. Clin Genet 58:341-4."
"487","NF960003","Lin AE, Birch PH, Korf BR, et al.  2000.  Cardiovascular malformations and other cardiovascular abnormalities in neurofibromatosis.  Am J Hum Gene 95:108-117."
"488","NF960003","Rasmussen SA, Yang Q, Friedman JM (2001): Mortality in neurofibromatosis 1: an analysis using U.S. death certificates. Am J Hum Genet 68:1110-8."
"489","NF960003","Stevenson DA, Birch PH, Friedman JM, et al.  1999.  Descriptive analysis of tibial pseudarthrosis in patients with neurofibromatosis 1.  Am J Med Genet 84(5):413-419."
"490","NF960003","Kwok ES, Sawatzky B, Birch P, Friedman JM, Tredwell SJ (2002): Vertebral scalloping in neurofibromatosis type 1: a quantitative approach. Can J Surg 45:181-4."
"491","NF960003","Friedman JM, Birch PH (1997): Type 1 neurofibromatosis: a descriptive analysis of the disorder in 1,728 patients. Am J Med Genet 70:138-43."
"492","NF960003","Szudek J, Birch P, Friedman JM (2000): Growth in North American white children with neurofibromatosis 1 (NF1). J Med Genet 37:933-8."
"493","NF960003","Baser ME, Birch PH, Evans GR, Friedman JM (1999): Association of superficial plexiform and paraspinal neurofibromas in neurofibromatosis 1 (NF1). Neurology 52:1519-20."
"494","NF960003","Szudek J, Birch P, Riccardi VM, Evans DG, Friedman JM (2000): Associations of clinical features in neurofibromatosis 1 (NF1). Genetic Epidemiology 19:429-39."
"495","NF960003","Friedman JM (1999): Epidemiology of neurofibromatosis type 1. American Journal of Medical Genetics 89:1-6."
"496","NF960003","Szudek J, Birch P, Friedman JM (2000): Growth charts for young children with neurofibromatosis 1 (NF1). American Journal of Medical Genetics 92:224-8."
"497","NF960013","Muja N, Blackman SC, Le Breton GC, DeVries GH (2001): Identification and functional characterization of thromboxane A2 receptors in Schwann cells. J Neurochem 78:446-56."
"498","NF960013","Lopez TJ, De Vries GH (1999): Isolation and serum-free culture of primary Schwann cells from human fetal peripheral nerve. Exp Neurol 158:1-8."
"499","NF960013","Badache A, Muja N, De Vries GH (1998): Expression of Kit in neurofibromin-deficient human Schwann cells: role in Schwann cell hyperplasia associated with type 1 neurofibromatosis. Oncogene 17:795-800."
"500","NF960013","Badache A, De Vries GH (1998): Neurofibrosarcoma-derived Schwann cells overexpress platelet-derived growth factor (PDGF) receptors and are induced to proliferate by PDGF BB. J Cell Physiol 177:334-42."
"501","NF960014","McInerney EM, Rose DW, Flynn SE, Westin S, Mullen TM, Krones A, Inostroza J, Torchia J, Nolte RT, Assa-Munt N, Milburn MV, Glass CK, Rosenfeld MG (1998): Determinants of coactivator LXXLL motif specificity in nuclear receptor transcriptional activation. Genes and Development 12:3357-68."
"502","NF960014","Bermingham JR Jr, Shumas S, Whisenhunt T, Rosenfeld MG, Scherer SS (2001): Modification of representational difference analysis applied to the isolation of forskolin-regulated genes from Schwann cells. Journal of the Neurological Sciences 63:516-24."
"503","NF960018","Ratner N and Daston MM.   (2001): Neurofibromatosis type 1 and Neurofibromatosis type 2:  Genetic and cellular mechanisms of peripheral nerve tumor formation. In: Glial cell development:  basic principles and clinical relevance. Jessen KR and Richardson WD, ed. Oxford University Press."
"504","NF960018","Atit RP, Mitchell K, Nguyen L, Warshawsky D, Ratner N (2000): The neurofibromatosis type 1 (Nf1) tumor suppressor is a modifier of carcinogen-induced pigmentation and papilloma formation in C57BL/6 mice. J Invest Dermatol 114:1093-100."
"505","NF960027","Thomson SA, Fishbein L, Wallace MR (2002): NF1 mutations and molecular testing. J Child Neurol 17:555-61; discussion 571-2, 646-51."
"506","NF960027","Messiaen LM, Callens T, Roux KJ, Mortier GR, De Paepe A, Abramowicz M, Pericak-Vance MA, Vance JM, Wallace MR (1999): Exon 10b of the NF1 gene represents a mutational hotspot and harbors a recurrent missense mutation Y489C associated with aberrant splicing. Genet Med 1:248-53."
"507","NF960027","Thomson SA, Wallace MR (2002): RT-PCR splicing analysis of the NF1 open reading frame. Hum Genet 110:495-502."
"508","NF960027","Rasmussen SA, Overman J, Thomson SA, Colman SD, Abernathy CR, Trimpert RE, Moose R, Virdi G, Roux K, Bauer M, Rojiani AM, Maria BL, Muir D, Wallace MR (2000): Chromosome 17 loss-of-heterozygosity studies in benign and malignant tumors in neurofibromatosis type 1. Genes Chromosomes Cancer 28:425-31."
"509","NF960034","LaJeunesse DR, McCartney BM, Fehon RG (2001): A systematic screen for dominant second-site modifiers of Merlin/NF2 phenotypes reveals an interaction with blistered/DSRF and scribbler. Genetics 158:667-79."
"510","NF960039","Friedman, J. M., Gutmann, D. H., MacCollin, M., and Riccardi, V. (1999): The Johns Hopkins University Press."
"511","NF960039","Kluwe L, Mautner V, Xin W et al. (2000): Molecular determination of somatic mosaicism in typical NF2 patients. American Journal of Human Genetics 67:2254."
"512","NF960039","Patronas NJ, Courcoutsakis N, Bromley CM, Katzman GL, MacCollin M, Parry DM (2001): Intramedullary and spinal canal tumors in patients with neurofibromatosis 2: MR imaging findings and correlation with genotype. Radiology 218:434-42."
"513","NF960039","Egan RA, Thompson CR, MacCollin M, Lessell S (2001): Monocular elevator paresis in neurofibromatosis type 2. Neurology 56:1222-4."
"514","NF960039","Jacoby LB, MacCollin M, Parry DM, Kluwe L, Lynch J, Jones D, Gusella JF (1999): Allelic expression of the NF2 gene in neurofibromatosis 2 and schwannomatosis. Neurogenetics 2:101-8."
"515","NF960039","Kluwe L, Mautner V, Parry DM, Jacoby LB, Baser M, Gusella J, Davis K, Stavrou D, MacCollin M (2000): The parental origin of new mutations in neurofibromatosis 2. Neurogenetics 3:17-24."
"516","NF960039","MacCollin M, Mautner VF (1998): The diagnosis and management of neurofibromatosis 2 in childhood. Semin Pediatr Neurol 5:243-52."
"517","NF960039","MacCollin M, Gutmann DH, Korf B, Finkelstein R (2001): Establishing priorities in neurofibromatosis research: a workshop summary. Genet Med 3:212-7."
"518","NF960041","McClatchey AI., Saotome I., Mercer K. et al. 1998. Mice heterozygous for a mutation at the Nf2 tumor suppressor locus develop a range of highly metastatic tumors. Genes Dev. 12:1121-1133."
"519","NF960041","Cichowski K, Shih TS, Schmitt E, Santiago S, Reilly K, McLaughlin ME, Bronson RT, Jacks T (1999): Mouse models of tumor development in neurofibromatosis type 1. Science 286:2172-6."
"520","NF960041","Reilly KM, Loisel DA, Bronson RT, McLaughlin ME, Jacks T (2000): Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects. Nature Genetics 26:109-13."
"521","NF960043","Shen S, Battersby S, Weaver M, Clark E, Stephens K, Harmar AJ (2000): Refined mapping of the human serotonin transporter (SLC6A4) gene within 17q11 adjacent to the CPD and NF1 genes. European Journal of Human Genetics 8:75-8."
"522","NF960043","Cooper LJ, Shannon KM, Loken MR, Weaver M, Stephens K, Sievers EL (2000): Evidence that juvenile myelomonocytic leukemia can arise from a pluripotential stem cell. Blood 96:2310-2313."
"523","NF960043","Dorschner MO, Sybert VP, Weaver M, Pletcher BA, Stephens K (2000): NF1 microdeletion breakpoints are clustered at flanking repetitive sequences. Human Molecular Genetics 9:35-46."
"524","NF960043","López-Correa C, Dorschner M, Brems H, et al.  2001.  Recombination hotspot in NF1 microdeletion patients. Hum Mol Genet. 10(13):1387-1392."
"525","NF960043","Stephens K., Weaver M., Leppig KA., et al. 2006. Interstitial uniparental isodisomy at clustered breakpoint intervals is a frequent mechanism of NF1 inactivation in myeloid malignancies. Blood. 108:1684-1689"
"526","NF960044","Vogel KS, El-Afandi M, Parada LF (2000): Neurofibromin negatively regulates neurotrophin signaling through p21ras in embryonic sensory neurons. Molecular and Cellular Neurosciences 15:398-407."
"527","NF960044","Gonzalez-Zulueta M, Feldman AB, Klesse LJ, Kalb RG, Dillman JF, Parada LF, Dawson TM, Dawson VL (2000): Requirement for nitric oxide activation of p21(ras)/extracellular regulated kinase in neuronal ischemic preconditioning. Proceedings of the National Academy of Sciences of the United States of America 97:436-41."
"528","NF960044","Vogel KS, Klesse LJ, Velasco-Miguel S, Meyers K, Rushing EJ, Parada LF (1999): Mouse tumor model for neurofibromatosis type 1. Science 286:2176-9."
"529","NF960044","Klesse LJ, Parada LF (1999): Trks: signal transduction and intracellular pathways. Microscopy Research and Technique 45:210-6."
"530","NF960044","Vogel KS, Parada LF (1998): Sympathetic neuron survival and proliferation are prolonged by loss of p53 and neurofibromin. Molecular and Cellular Neurosciences 11:19-28."
"531","NF960044","Klesse LJ, Parada LF (1998): p21 ras and phosphatidylinositol-3 kinase are required for survival of wild-type and NF1 mutant sensory neurons. Journal of Neuroscience 18:10420-8."
"532","NF960044","Klesse LJ, Meyers KA, Marshall CJ, Parada LF (1999): Nerve growth factor induces survival and differentiation through two distinct signaling cascades in PC12 cells. Oncogene 18:2055-68."
"533","NF960048","Weiss B, Bollag G, Shannon K (1999): Hyperactive Ras as a therapeutic target in neurofibromatosis type 1. Am J Med Genet 89:14-22."
"534","NF960051","Blaydes SM, Kogan SC, Truong BT, Gilbert DJ, Jenkins NA, Copeland NG, Largaespada DA, Brannan CI (2001): Retroviral integration at the Epi1 locus cooperates with Nf1 gene loss in the progression to acute myeloid leukemia. J Virol 75:9427-34."
"535","NF960051","Costa RM, Yang T, Huynh DP, Pulst SM, Viskochil DH, Silva AJ, Brannan CI (2001): Learning deficits, but normal development and tumor predisposition, in mice lacking exon 23a of Nf1. Nat Genet 27:399-405."
"536","NF960063","Shaw RJ, Paez JG, Curto M, Yaktine A, Pruitt WM, Saotome I, O'Bryan JP, Gupta V, Ratner N, Der CJ, Jacks T, McClatchey AI (2001): The Nf2 tumor suppressor, merlin, functions in Rac-dependent signaling. Dev Cell 1:63-72."
"537","NF970002","Poussaint TY, Jaramillo D, Chang Y, et al. 2003.  Interobserver reproducibility of volumetric MR imaging measurements of plexiform neurofibromas.  Am J Radiol 180:419-423."
"538","NF970002","·Mautner VF, Friedrich RE, von Deimling A, et al.  2003.  Malignant peripheral nerve sheath tumours in neurofibromatosis type 1: MRI supports the diagnosis of malignant plexiform neurofibroma.  Neuroradiology 45:618-625.
"
"539","NF970002","·Friedrich RE, Korf B, Funsterer C, et al.  2003.  Growth type of plexiform neurofibromas in NF1 determined on magnetic resonance images.  Anticancer Research 23:949-952.
"
"540","NF970002","Korf BR (2002): Determination of end points for treatment of neurofibromatosis 1. J Child Neurol 17:642-5; discussion 646-51."
"541","NF970002","Dombi E, Solomon J, Gillespie AJ, et al.  2007.  NF1 plexiform neurofibroma growth rate by volumetric MRI.  Neurol 68:643-647."
"542","NF970002","Fuller CE, Perry A (2002): Fluorescence in situ hybridization (FISH) in diagnostic and investigative neuropathology. Brain Pathol 12:67-86."
"543","NF970002","Perry A, Roth KA, Banerjee R, Fuller CE, Gutmann DH (2001): NF1 deletions in S-100 protein-positive and negative cells of sporadic and neurofibromatosis 1 (NF1)-associated plexiform neurofibromas and malignant peripheral nerve sheath tumors. Am J Pathol 159:57-61."
"544","NF970002","Lim R, Jaramillo D, Poussaint TY, et al.  2005.  Superficial neurofibromatosis: A lesion with unique MR characteristics in patients with neurofibromatosis type 1. AM J Roentgenol 184:962."
"545","NF970002","Zacharia TT, Jaramillo D, Poussaint TY, et al.  2004. MR imaging of abdominopelvic involvement in neurofibromatosis type 1: A review of 43 patients.  Ped Radiol 35:317-22."
"546","NF970002","Kluwe L, Friedrich RE, Korf B, Fahsold R, Mautner VF (2002): NF1 mutations in neurofibromatosis 1 patients with plexiform neurofibromas. Hum Mutat 19:309."
"547","NF980004","·Lallemand D, M Curto, I Saotome, et al., 2003.  NF2 deficiency promotes tumorigenesis and metastasis by destabilizing adherens junctions.  Genes & Development 17:1090-1100.
"
"548","NF980007","·Packer R, Gutnabb D, Rubenstein A, et al.  2002.  Plexiform neurofibromas in NF1: Towards biologic-based therapy.  Neurology 58:1461-1470."
"549","NF980007","·Mukhopadhyay D, Anant S, Lee R, et al.  2002.  C to U editing of neurofibromatosis 1 mRNA occurs in tumors that express the type II transcript and that also express apobec-1, the catalytic subunit of the apolipoprotein B mRNA editing enzyme.  Am. J. Human Genetics 70:38-50."
"550","NF980007","Liew MA, Coffin CM, Fletcher JA, Hang MT, Tanito K, Niimura M, Viskochil D (2002): Peripheral nerve sheath tumors from patients with neurofibromatosis type 1 do not have the chromosomal translocation t(X;18). Pediatr Dev Pathol 5:165-9."
"551","NF980010","Scoles DR, Huynh DP, Chen MS, Burke SP, Gutmann DH, Pulst SM (2000): The neurofibromatosis 2 tumor suppressor protein interacts with hepatocyte growth factor-regulated tyrosine kinase substrate. Hum Mol Genet 9:1567-74."
"552","NF980010","Gutmann DH, Haipek CA, Burke SP, Sun CX, Scoles DR, Pulst SM (2001): The NF2 interactor, hepatocyte growth factor-regulated tyrosine kinase substrate (HRS), associates with merlin in the 'open' conformation and suppresses cell growth and motility. Hum Mol Genet 10:825-34."
"553","NF980010","Scoles DR, Nguyen VD, Qin Y, Sun CX, Morrison H, Gutmann DH, Pulst SM (2002): Neurofibromatosis 2 (NF2) tumor suppressor schwannomin and its interacting protein HRS regulate STAT signaling. Hum Mol Genet 11:3179-89."
"554","NF980010","Sun CX, Haipek C, Scoles DR, Pulst SM, Giovannini M, Komada M, Gutmann DH (2002): Functional analysis of the relationship between the neurofibromatosis 2 tumor suppressor and its binding partner, hepatocyte growth factor- regulated tyrosine kinase substrate. Hum Mol Genet 11:3167-78."
"555","NF980010","Costa RM, Yang T, Huynh DP, Pulst SM, Viskochil DH, Silva AJ, Brannan CI (2001): Learning deficits, but normal development and tumor predisposition, in mice lacking exon 23a of Nf1. Nat Genet 27:399-405."
"556","NF980010","Scoles DR, Chen M, Pulst SM (2002): Effects of Nf2 missense mutations on schwannomin interactions. Biochem Biophys Res Commun 290:366-74."
"557","NF980011","·Miller SJ, Rizvi TA, Huang Y, et al.  2003.  Brain lipid binding protein in axon-schwann cell interactions and peripheral nerve tumorrigenesis.  Mol. Cell. Bio. 23:2213-2224.
"
"558","NF980012","Hannan F., Ho I., Tong, et al. 2006. Effect of neurofibromatosis type 1 mutations on  a novel pathway for adenylyl cyclase activation requiring neurofibromin and Ras. Hum Mol Genet. 15:1087-1098."
"559","NF980012","Guo HF, Tong J, Hannan F, Luo L, Zhong Y (2000): A neurofibromatosis-1-regulated pathway is required for learning in Drosophila. Nature 403:895-8."
"560","NF980015","Breton S, Wiederhold T, Marshansky V, Nsumu NN, Ramesh V, Brown D (2000): The B1 subunit of the H+ATPase is a PDZ domain-binding protein. Colocalization with NHE-RF in renal B-intercalated cells. J Biol Chem 275:18219-24."
"561","NF980015","James MF, Manchanda N, Gonzalez-Agosti C, Hartwig JH, Ramesh V (2001): The neurofibromatosis 2 protein product merlin selectively binds F- actin but not G-actin, and stabilizes the filaments through a lateral association. Biochem J 356:377-86."
"562","NF980015","Stemmer-Rachamimov AO, Wiederhold T, Nielsen GP, James M, Pinney-Michalowski D, Roy JE, Cohen WA, Ramesh V, Louis DN (2001): NHE-RF, a merlin-interacting protein, is primarily expressed in luminal epithelia, proliferative endometrium, and estrogen receptor-positive breast carcinomas. Am J Pathol 158:57-62."
"563","NF980015","Tang Y, Tang J, Chen Z, Trost C, Flockerzi V, Li M, Ramesh V, Zhu MX (2000): Association of mammalian trp4 and phospholipase C isozymes with a PDZ domain-containing protein, NHERF. J Biol Chem 275:37559-64."
"564","NF980018","Fieber LA. 2003.  Voltage-Gated ion currents of schwann cells in cell culture models of human neurofibromatosis. J Exp Zool A Comp Exp Biol300(1):76-83."
"565","NF980018","Fieber LA, Gonzalez DM, Wallace MR, Muir D (2003): Delayed rectifier K currents in NF1 Schwann cells. Pharmacological block inhibits proliferation. Neurobiol Dis 13:136-46."
"566","NF990007","Hyman SL, Gill DS, Shores EA, et al. 2003. Natural history of cognitive deficits and their relationship to MRI T2-hyperintensities in NF1. Neurology 60:1139-1145."
"567","NF990007","Hyman SL, Gill DS, Shores EA, Steinberg A, Joy P, Gibikote SV, North KN (2003): Natural history of cognitive deficits and their relationship to MRI T2- hyperintensities in NF1. Neurology 60:1139-45."
"568","NF990007","Hyman SL, Arthur Shores E, and North KN.  2006.  Learning disabilities in children with neurofibromatosis type 1: subtypes, cognitive profile, and attention-deficit-hyperactivity disorder.  Dev Med Child Neurol 48: 973-977."
"569","NF990007","Hyman SL, Shores A, and North KN.  2005. The nature and frequency of cognitive deficits in children with neurofibromatosis type 1. Neurology 65:1037-1044."
"570","NF990007","Gill DS, Hyman SL, Steinberg A, North KN.  2006.  Age-related findings on MRI in neurofibromatosis type 1. Pediatr Radiol 36(10):1048-56
"
"571","NF990007","Barton B, and North K (2004) Social skills of children with neurofibromatosis type 1. Dev Med Child Neurol 46(8):553-63."
"572","NF990007","Barton B, and North KN. 2007.  The development of self-concept in children and adolescents with NF1. Child Care Health and Development 33(4):401-408."
"573","NF990007","Hyman SL, Gill DS, Shores EA, et al.  2007.  T2 hyperintensities in children with neurofibromatosis type 1 and their relationship to cognitive functioning. J Neurol Neurosurg Psychiatry 78(10):1088-91."
"574","NF990008","Kurtz A, Lueth M, Kluwe L, et al. 2004. Somatic mitochondrial DNA mutations in neurofibromatosis type 1-associated tumors. Mol Cancer Res. 2(8):433-41."
"575","NF990010","·Erickson RP, S Skinner, H Jacquet, et al., 2003.  Does chromosome 22 have anything to do with sex determination:  Further studies on a 46,XX,22q11.2 Del Male.  American Journal of Medical Genetics 123A:64-67."
"576","NF990010","·Mantripragada KK, PG Buckley, M Benetkiewicz, et al., 2003.  High-resolution profiling of an 11 Mb segment of human chromosome 22 in sporadic schwannoma using array-CGH.  International Journal of Oncology 22:615-622."
"577","NF990010","·Hansson CM, H Ali, CE Bruder, et al., 2003.  Strong conservation of the human NF2 locus based on sequence comparison in five species.  Mammalian Genome 14:526-536.

"
"578","NF990010","·Buckley PG, KK Mantripragada, M Benetkiewicz, et al., 2002.  A full-coverage, high-resolution human chromosome 22 genomic microarray for clinical and research applications.  Human Molecular Genetics 11:3221-3229."
"579","NF990010","·Mantripragada KK, I Tapia-Paez, E Blennow, et al., 2003.  
DNA copy-number analysis of the 22q11 deletion-syndrome region using array-CGH with genomic and PCR-based targets.  International Journal of Molecular Medicine, in press.
"
"580","NF990010","·Mantripragada KK, PG Buckley, T Diaz de Stahl, and JP Dumanski, 2003.  Genomic microarrays in the spotlight.  Trends in Genetics, 20:87-94."
"581","NF990010","Bruder CE, Hirvela C, Tapia-Paez I, Fransson I, Segraves R, Hamilton G, Zhang XX, Evans DG, Wallace AJ, Baser ME, Zucman-Rossi J, Hergersberg M, Boltshauser E, Papi L, Rouleau GA, Poptodorov G, Jordanova A, Rask-Andersen H, Kluwe L, Mautner V, Sainio M, Hung G, Mathiesen T, Moller C, Pulst SM, Harder H, Heiberg A, Honda M, Niimura M, Sahlen S, Blennow E, Albertson DG, Pinkel D, Dumanski JP (2001): High resolution deletion analysis of constitutional DNA from neurofibromatosis type 2 (NF2) patients using microarray-CGH. Hum Mol Genet 10:271-82."
"582","NF990010","Mantripragada KK, PG Buckley, C Jarbo, et al., 2003.  Development of NF2 gene specific, strictly sequence defined diagnostic microarray for deletion detection.  Journal of Molecular Medicine 81:443-451."
"583","NF990013","Messerli SM, Prabhakar S, Tang Y, et al.  2006.  Treatment of schwannomas with an oncolytic recombinant herpes simplex virus in murine models of neurofibromatosis type 2. Hum Gene Ther.17(1):20-30."
"584","NF990013","Prabhaker S, Brenner GJ., Sena-Esteves M. et al. 2010. Imaging and therapy of experimental schwannomas using HSV amplicon vector encoding apoptotic protein under Schwann cell promoter. Cancer Gene Therapy.17:266-274."
"585","NF990013","Prabhakar S., Messerli SM., Stemmer-Rachamimov AO., et al. 2007. Treatment of implantable NF2 schwannoma tumor models with oncolytic herpes simplex virus G47. Cancer Gene Ther. 14:460-2007"
"586","NF990013","·Tang Y, Shah K, Messerli SM, et al. 2003. In vivo tracking of neural progenitor cell migration to glioblastomas. Human Gene Therapy 14:1247-1254."
"587","NF990013","·Messerli SM, Tang Y, Giovannini M, et al. 2002. Detection of spontaneous schwannomas by MRI in a transgenic murine model of neurofibromatosis type 2 (NF2). Neoplasia 4:501-509."
"588","NF990013","Prabhakar S, Messerli SM, Stemmer-Rachamimov AO, et al. 2007. Treatment of implantable NF2 schwannoma tumor models with oncolytic herpes simplex virus G47Delta.  Cancer Gene Ther 14(5):460-467.

"
"589","NF990018","Gutmann DH, Wu YL, Hedrick NM, Zhu Y, Guha A, Parada LF (2001): Heterozygosity for the neurofibromatosis 1 (NF1) tumor suppressor results in abnormalities in cell attachment, spreading and motility in astrocytes. Hum Mol Genet 10:3009-16."
"590","NF990018","Johnson KC, Kissil JL, Fry JL, Jacks T (2002): Cellular transformation by a FERM domain mutant of the Nf2 tumor suppressor gene. Oncogene 21:5990-7."
"591","NF990018","Kalamarides M, Niwa-Kawakita M, Leblois H, Abramowski V, Perricaudet M, Janin A, Thomas G, Gutmann DH, Giovannini M (2002): Nf2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in the mouse. Genes Dev 16:1060-5."
"592","NF990018","Zhu Y, Romero MI, Ghosh P, Ye Z, Charnay P, Rushing EJ, Marth JD, Parada LF (2001): Ablation of NF1 function in neurons induces abnormal development of cerebral cortex and reactive gliosis in the brain. Genes Dev 15:859-76."
"593","NF990018","McClatchey AI, Cichowski K (2001): Mouse models of neurofibromatosis. Biochim Biophys Acta 1471:M73-80."
"594","NF990018","Messerli SM, Tang Y, Giovannini M, Bronson R, Weissleder R, Breakefield XO (2002): Detection of spontaneous schwannomas by MRI in a transgenic murine model of neurofibromatosis type 2. Neoplasia 4:501-9."
"595","NF990018","Parada LF (2000): Neurofibromatosis type 1. Biochim Biophys Acta 1471:M13-9."
"596","NF990018","Gutmann DH, Giovannini M (2002): Mouse models of neurofibromatosis 1 and 2. Neoplasia 4:279-90."
"597","NF990018","Gautreau A, Manent J, Fievet B, Louvard D, Giovannini M, Arpin M (2002): Mutant products of the NF2 tumor suppressor gene are degraded by the ubiquitin-proteasome pathway. J Biol Chem 277:31279-82."
"598","NF990018","Donovan S, Shannon KM, Bollag G (2002): GTPase activating proteins: critical regulators of intracellular signaling. Biochim Biophys Acta 1602:23-45."
"599","NF990018","Denisenko-Nehrbass N, Goutebroze L, Galvez T, Bonnon C, Stankoff B, Ezan P, Giovannini M, Faivre-Sarrailh C, Girault JA (2003): Association of Caspr/paranodin with tumour suppressor schwannomin/merlin and beta1 integrin in the central nervous system. J Neurochem 84:209-21."
"600","NF990018","Bajenaru ML, Zhu Y, Hedrick NM, Donahoe J, Parada LF, Gutmann DH (2002): Astrocyte-specific inactivation of the neurofibromatosis 1 gene (NF1) is insufficient for astrocytoma formation. Mol Cell Biol 22:5100-13."
"601","NF990018","Aiyagari AL, Taylor BR, Aurora V, Young SG, Shannon KM (2003): Hematologic effects of inactivating the Ras processing enzyme Rce1. Blood 101:2250-2."
"602","NF990018","Li H, Velasco-Miguel S, Vass WC, Parada LF, DeClue JE (2002): Epidermal growth factor receptor signaling pathways are associated with tumorigenesis in the Nf1:p53 mouse tumor model. Cancer Res 62:4507-13."
"603","NF990018","Le DT, Shannon KM (2002): Ras processing as a therapeutic target in hematologic malignancies. Curr Opin Hematol 9:308-15."
"604","NF990018","Kissil JL, Johnson KC, Eckman MS, Jacks T (2002): Merlin phosphorylation by p21-activated kinase 2 and effects of phosphorylation on merlin localization. J Biol Chem 277:10394-9."
"605","NF990018","Zhu Y, Parada LF (2001): Neurofibromin, a tumor suppressor in the nervous system. Exp Cell Res 264:19-28."
"606","NF990018","Shannon KM, Le Beau MM, Largaespada DA, Killeen N (2001): Modeling myeloid leukemia tumor suppressor gene inactivation in the mouse. Semin Cancer Biol 11:191-200."
"607","NF990018","Weiss B, Shannon K (2003): Mouse cancer models as a platform for performing preclinical therapeutic trials. Curr Opin Genet Dev 13:84-9."
"608","NF990018","Zhu Y and Parada LF (2002): The molecular and genetic basis of neurologic tumors. Nature Reviews on Cancer 2:616."
"609","NF990018","Gitler AD, Zhu Y, Ismat FA, Lu MM, Yamauchi Y, Parada LF, Epstein JA (2003): Nf1 has an essential role in endothelial cells. Nat Genet 33:75-9."
"610","NF990018","Zhu Y, Ghosh P, Charnay P, Burns DK, Parada LF (2002): Neurofibromas in NF1: Schwann cell origin and role of tumor environment. Science 296:920-2."
"611","NF990020","Su W, Sin M, Darrow A, Sherman LS (2003):  Malignant peripheral nerve sheath tumor cell invasion is facilitated by Src and aberrant CD44 expression. Glia  42:350-358."
"612","NF990020","Su W, Gutmann DH, Perry A, et al.  2003.  CD44-independent hepatocyte growth factor/c-Met autocrine loop promotes malignant peripheral nerve sheath tumor cell invasion in vitro.  Glia 45:297-306.
"
"613","NF990022","Bonneau F, D¿Angelo I, Welti S, et al.  2004.  Expression, purification and preliminary crystallographic characterization of a novel segment from the neurofibromatosis type 1 protein. Acta Crystallographica D60:2364-2367."
"614","NF990022","D'Angelo I, Welti S, Bonneau F, Scheffzek K. 2006. A novel bipartite phospholipid-binding module in the neurofibromatosis type 1 protein. 
EMBO Rep. 7(2):174-9."
"615","NF990024","Zou M, Butcher D, Sadikovic B, et al. 2004. Characterization of functional elements in the neurofibromatosis (NF1) proximal promoter region. Oncogene 23:330-339."
"616","NF990031","Stephens K.  2004.  Neurofibromatosis.  In Molecular Pathology in Clinical Practice.  Eds. Leonard DGB, Bagg A, Caliendo A, et al.  Spring-Verlag."
"617","NF990031","·Stephens K.  2003.  Genetics of neurofibromatosis 1 associated peripheral nerve sheath tumors.  Cancer Invest. 21;897-914"
"618","NF990031","Messiaen L, Riccardi V, Peltonen J, Maertens O, Callens T, Karvonen SL, Leisti EL, Koivunen J, Vandenbroucke I, Stephens K, Poyhonen M (2003): Independent NF1 mutations in two large families with spinal neurofibromatosis. J Med Genet 40:122-6."
"619","NF990031","Lopez-Correa C, Dorschner M, Brems H, Lazaro C, Clementi M, Upadhyaya M, Dooijes D, Moog U, Kehrer-Sawatzki H, Rutkowski JL, Fryns JP, Marynen P, Stephens K, Legius E (2001): Recombination hotspot in NF1 microdeletion patients. Hum Mol Genet 10:1387-92."
"620","NF990031","Cooper LN, Shannon KM, Loken MR, et al.  2000.  Evidence that juvenile myelomonocytic leukemia can arise from a pluripotential stem cell.  Blood 96:2310-2313."
"621","NF990031","Forbes SH, Dorschner MO, Le R, et al.  2004.  Genomic context of paralogous recombination hotspots mediating the recurrent NF1 region microdeletion.  Genes Chromosomes Cancer 41:12-25."
"622","NF990031","Jenne DE, Tinschert S, Dorschner MO, et al.  2003.  Complete physical map and gene content of the human NF1 tumor suppressor region in human and mouse.  Genes Chromosomes Cancer 37:111-120.

"
"623","NF990033","Scoles, D.R.,  Yong, W., Qin, Y., Wawrowsky, K. and Pulst, S.M. Schwannomin inhibits tumorigenesis through direct interaction with the eukaryotic initiation factor eIF3c.  Human Molecular Genetics 15:1059-1070; 2006."
"624","NF990033","Scoles, D.R., Qin, Y., Nguyen, V., Gutmann, D.H., and Pulst, S.M. HRS inhibits EGF receptor signaling in the RT4 rat schwannoma cell line.
Biochemical and Biophysical Research Communications. 335:385-392; 2005."
"625","NF990035","Mattingly RR, Milstein ML, Mirkin BL (2001): Down-regulation of growth factor-stimulated MAP kinase signaling in cytotoxic drug-resistant human neuroblastoma cells. Cell Signal 13:499-505."
"626","NF990035","Mattingly RR, Gibbs RA, Menard RE, Reiners JJ Jr (2002): Potent suppression of proliferation of a10 vascular smooth muscle cells by combined treatment with lovastatin and 3-allylfarnesol, an inhibitor of protein farnesyltransferase. J Pharmacol Exp Ther 303:74-81."
"627","NF990035","Mattingly R, Kranial J, Dillworth A, et al. 2006.  The mitogen-activated protein
kinase/extracellular signal-regulated kinase kinase inhibitor PD184352 (CI-1040)selectively induces apoptosis in malignant schwannoma cell lines. J Pharmacol Exp Ther 316(1):456-465."
"628","NF990038","Baser ME, L Kuramoto, H Joe, et al., 2004.  Genotype-phenotype correlations for nervous system tumors in neurofibromatosis 2: A population-based study.  Am. J. Hum. Genet. 75:231-240.

"
"629","NF990038","Castle B, ME Baser, SM Huson, et al., 2003.  Evaluation of genotype-phenotype correlations in neurofibromatosis type 1.  J. Med. Genet. 40(10):109e."
"630","NF990038","Mautner VF, ME Baser, SD Thakkar, et al., 2002.  Vestibular schwannoma growth in patients with neurofibromatosis type 2:  A longitudinal study.  J. Neurossurg. 96(2):223-8.

"
"631","NF990038","Palmer V, J Szudek, H Joe, et al., 2004.  Analysis of neurofibromatosis 1 (nf1) lesions by body segment.  Am. J. Med. Genet. 125A:157-161."
"632","NF990038","Szudek J, Joe H, Friedman JM (2002): Analysis of intrafamilial phenotypic variation in neurofibromatosis 1 (NF1). Genet. Epidemiol 23:150-164."
"633","NF990038","Baser ME, Kuramoto L, Woods R, et al. 2005. The location of constitutional neurofibromatosis 2 (NF2) splice site mutations is associated with the severity of NF2. J Med Genet. 42(7):540-6. Review."
"634","NF990038","Woods R, Friedman JM, Evans DG, Baser ME, Joe H (2002): Exploring the 'two-hit hypothesis' in NF2: Tests of two-hit and three-hit models of vestibular schwannoma development. Genet. Epidemiol.  24:265-272."
"635","NF990038","Baser ME, Kuramoto L, Joe H, Friedman JM, Wallace AJ, Ramsden RT, Evans DG (2003): Genotype-phenotype correlations for cataracts in neurofibromatosis 2. J. Medical Genetics.  40:758-60."
"636","NF990038","Baser ME, Friedman JM, Aeschliman D, Joe H, Wallace AJ, Ramsden RT, Evans DG (2002): Predictors of the risk of mortality in neurofibromatosis 2. Am. J. Hum. Genet. 71:715-723 71:715-723."
"637","NF990038","Baser ME, Friedman JM, Wallace AJ, Ramsden RT, Joe H, Evans DG. (2002): Evaluation of clinical diagnostic criteria for neurofibromatosis 2. Neurology 59:1759-1765."
"638","NF990038","Zhao Y, Kumar RA, Baser ME, Evans DG, Wallace A, Kluwe L, Mautner VF, Parry DM, Rouleau GA, Joe H, Friedman JM. (2002): Intrafamilial correlation of clinical manifestations in neurofibromatosis 2 (NF2).  Genet. Epidemiol. 23:245-259."
"639","NF990043","Mykkanen OM, Gronholm M, Ronty M, Lalowski M, Salmikangas P, Suila H, Carpen O (2001): Characterization of human palladin, a microfilament-associated protein. Mol Biol Cell 12:3060-73."
"640","NF990043","Mologni L, Salmikangas P, Fougerousse F, Beckmann JS, Carpen O (2001): Developmental expression of myotilin, a gene mutated in limb-girdle muscular dystrophy type 1A. Mech Dev 103:121-5."
"641","NF990043","Gronholm M, Vossebein L, Carlson CR, et al. 2003. Merlin links to the cAMP signaling pathway by anchoring the RI-beta subunit of protein kinase A. J Biol Chem 278: 41167-41172."
"642","NF990043","Alfthan K, Heinska M, Gronholm GH, et al. 2004. Cyclic AMP-dependent protein kinase phosphorylates merlin at serine 518 independently of p21-activated kinase and promotes merlin-ezrin heterodimerization. J Biol Chem 279:18559-18566."
"643","NF990043","Grönholm M, Teesalu T, Tyynelä J, et al. 2005. Characterization of the NF2 protein merlin and the ERM protein ezrin in human, rat, and mouse central nervous system. Mol Cell Neurosci 28(4):683-693."
"644","NF990044","Cutting LE, Cooper KL, Koth CW, Mostofsky SH, Kates WR, Denckla MB, Kaufmann WE (2002): Megalencephaly in NF1: predominantly white matter contribution and mitigation by ADHD. Neurology 59:1388-94."
"645","NF990044","Cutting LE, Huang GH, Zeger S, Koth CW, Thompson RE, Denckl MB (2002): Growth curve analyses of neuropsychological profiles in children with neurofibromatosis type 1: specific cognitive tests remain 'spared' and 'impaired' over time. J Int Neuropsychol Soc 8:838-46."
"646","NF990044","Kraut MA, Gerring JP, Cooper KL, et al.  2004.  Longitudinal evolution of T2-weighted hyperintensities in children with neurofibromatosis type 1.  Am J Med Genet 129:113-119."
"647","NF990047","Muir D, Neubauer D, Lim IT, Yachnis AT, Wallace MR (2001): The tumorigenic properties of neurofibromin-deficient Schwann cell lines subcultured from the human neurofibromas. American Journal of Pathology  158:501-513."
"648","NF990047","Fieber LA, Gonzalez DM, Wallace MR, Muir D (2003): Delayed rectifier K currents in NF1 Schwann cells. Pharmacological block inhibits proliferation. Neurobiology of Disease  13: 136-146."